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Abstract
Water-based Lead Identification
By: Brian Olson
Advisor: Thomas Kurtzman

The opioid epidemic and the SARS-CoV-2 pandemic are current serious challenges whose
devastating effects could be assuaged through the development of new drugs. Opioids that are
functional painkillers, that are less likely to cause overdose, and small molecule drugs that could
inhibit the life cycle of SARS-CoV-2 would be useful. The work herein investigated the use of water
molecules for lead generation in drug development against opioid receptors and SARS-CoV-2 viral
proteins. In opioid receptor binding sites, purported bridging waters were obtained from crystal
waters or from molecular dynamics simulations, as Hydration Site Analysis was used to predict
the locations and orientations of bridging water molecules. Hydration Site Analysis and Grid
Inhomogeneous Solvation Theory were used to analyze solvated binding sites of SARS-CoV-2
proteins, to predict the locations and orientations of water molecules and to produce
thermodynamic analyses of water, which are useful to score solvation displacement in docking,
inform lead modification, and create water-based pharmacophores, hybrid ligand- and waterbased pharmacophores, and provide criteria to prioritize the selection of pharmacophore sites.
This work demonstrated that the inclusion of bridging waters during ligand-receptor docking to
opioid receptors improved docking enrichment by enhancing binding affinities via H-bond and
electrostatic interactions and, in some cases, improved pose prediction. Inclusion of bridging
water molecules helped to enrich known actives with or without a ligand core similar to the cocrystallized compound, and selection of ligands (for whom interactions with bridging waters are
important) can be automated. Inside the substrate binding site of SARS-CoV-2 main protease, we
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find energetically unfavorable hydration sites whose displacement may lead to boosts in binding
affinity, solvated regions of favorable or unfavorable energy density for use in a displaced solvent
functional, and interesting hydration sites to create water-based pharmacophore elements for
lone use, in combination with other ligand-based or structure-based pharmacophore elements,
or for use in the prioritization of ligand- or structure-based pharmacophore elements.
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1 Introduction
1.1A WATER-BASED LEAD GENERATION
Water plays a significant role in the recognition between drugs and their biomolecular
targets. When a drug binds, water is displaced from the binding site into bulk “biological” water
where the water has different entropic and energetic properties. These differences contribute
significantly to the free energy of drug binding and it is widely believed that these can be the
dominant contributions, having an importance equal to or greater than the direct drug-protein
interactions. Upon drug binding, water can also remain in the binding site to either mediate
interactions (e.g. bridging waters) between the ligand and protein or restructure themselves
around the newly formed complex. Both reorganization of water molecules and mediation of
ligand-receptor interactions can make significant contributions to the free energy of molecular
recognition.
Despite this, traditional computational methods that aim to identify molecules that bind
to a particular protein target (such as docking) do not include the thermodynamic contributions
of water, neither their displacement, mediation, nor restructuring. Historically, this may be due
to the complexity of treating water. Indeed, water molecules can change positions and rotate to
mediate interactions and predicting how they do so can be difficult. Also, accounting for the
entropy and energetic changes of water displacement and reorganization, while recognized as
important1,2,3,4, has been historically difficult to quantify and remains a current theoretical and
computational challenge in modeling. In recent years, methods that produce three-dimensional
maps of water properties on surfaces of proteins have helped to alleviate these problems, but
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full advantage has yet to be taken as to whether and how these methods can improve
computational drug discovery and design.
A popular computational method of screening compounds is molecular docking. Docking
methodologies seek biologically active compounds through the prediction of poses and affinities
of small molecules inside the binding sites of receptor targets. Docking tools include a search
algorithm for generating ligand poses and a scoring function for evaluation of ligand poses.
Docking methods have traditionally scored the viability of potential binding molecules by their
direct interactions (hydrophobic, hydrophilic, and electrostatic). The traditional scoring methods
incorporate water indirectly (e.g. the free energy of forming hydrophobic surface contacts is
generally presumed to originate from water thermodynamics) and the incorporation of water is
incomplete (e.g. docking methods include an approximate term for ligand desolvation, but not
for solvent reorganization, mediation, or solvent displacement). There have been a number of
efforts in recent years from our lab and others to help rectify this problem5,6,7,8,9,10,11,12,13,14,15,16,17.
One topic explored in this thesis is addressing the particularly challenging problem of
identifying and accounting for the mediation of water molecules in docking. Inclusion of key
explicit water molecules during ligand-receptor docking has been shown to improve docking
performance and the poses of docked ligands18,19,20,21,22,23,24,25. The inclusion of explicit water
molecules during virtual screening has also been shown to improve the enrichment of active
compounds20,26. Water molecules have been used in comparative ligand-receptor docking
methods, docking in the presence of explicit water or without water 18,19,20,27,28, and the docking
improvements made in the presence of water can be independent of the optimization method
of the orientation of water molecules29. The variable selection of binding site waters has been
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shown to have a demonstrable effect on virtual screening 24,26, even when using water positions
and orientations obtained from molecular dynamics simulations24,25,30. Locations and
orientations of water molecules have been predicted using a force field31. Locations of discrete
water molecules have been predicted during docking using placement of objects (called
“particles”) that can form molecular interactions (e.g. hydrogen bonds, steric interactions) within
the binding site of the protein32, and these placed waters could be switched on and off during
fragment-based construction of ligands inside the binding site. Another method allows waters to
be switched on and off, and rotate around three axes, using a penalty to reward water
displacement33. Yet another method docks flexible ligands into flexible proteins while accounting
for the presence of “displaceable” bridging waters taken from x-ray crystal structure models34.
Mediating waters have also been identified using MD simulation with geometric analyses of
intramolecular bonds in water molecules to identify unchanged or slightly shortened H—O bond
lengths1/28/2022 5:31:00 PM21, and a method that uses the HINT free energy scoring model
combined with the Rank algorithm that calculates the number and geometric quality of hydrogen
bonds for each bridging water molecule35,36. Other methods solvate the ligand and then flexibly
dock the solvated ligand as the waters are retained or displaced depending on entropy and or
energy contributions during the simulation31,37. Even when the locations and orientations of
coordinated bridging waters have been predicted, optimization of bridging water molecules and
bridging water networks, in particular, remains difficult35.
Barriers to the prediction and use of bridging waters include:
1. Crystal structures my lack the resolution required to identify crystallographic waters.
2. X-ray crystallographers are inconsistent in the effort extended to place water molecules.
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3. Water molecules may move or change orientation.
4. Active sites are often co-crystallized with a ligand, so the locations of waters displaced by a
ligand are unavailable. *Note: our method addresses this as we place water with simulations.
5. Water placement can create steric conflicts if water is placed as part of the target molecule.
A potential ligand can only interact with the water and not displace it. Some ligands will
interact with the water and some may displace it.

A major focus of this thesis is whether we can identify water positions based on
computational methods, whether that method reproduces select known crystal waters and, if
we place waters using this computational method, whether we see corresponding improvements
in docking metrics (AUC and pose prediction). We address whether individual candidate docked
ligands interact with bridging molecules using an algorithm (in a script) that compiles a list of
ligands whose Glide Score decreases when docked in the presence of three bridging waters
versus that same ligand docked without bridging waters, whose Glide Scores decrease with the
sequential addition of bridging water molecules, and whose ligand pose remains reasonable
(RMSD < 2.00 Å) when docked in the presence of bridging waters. We assess the docked pose for
any ligand that contains a benzomorphan core as that core is present in the co-crystallized ligand.
Other ligands without benzomorphan cores are evaluated based on changes in Glide Scores with
the addition of bridging waters. Thereby, we identify compounds that interact with the bridging
water and for whom mediation is important.
Water also provides important information that can be exploited in drug discovery and
design settings.
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1. Water displacement can be used to improve docking outcomes as measured by AUC, for the
prospective identification of novel compounds, and for pose prediction13,14,38,39,40.
2. Water molecules tend to make similar contacts with a protein as the ligands that displace
them. Generally, when a ligand donates/accepts a hydrogen bond, it replaces a water
molecule that was doing the same, and hydrophobic contacts between protein-and ligand
displace water that is not making H-bonds with the surface. Three-dimensional interaction
maps of these water-protein interactions can be used to create pharmacophores or expand
traditional and protein structure based and ligand-based pharmacophores15,41,42.
3. Rational lead modification can also be informed by water. Modifications to an existing lead
generally should or must make contacts with the protein in the same way as the water these
new chemical groups displace. The thermodynamics and structural properties of water may
identify lead modifications into regions that will provide gains in specificity 43,44,45 or
affinity13,15,38,43,46.

Ignoring water molecules in binding sites may reduce the chance that a drug design
project will be successful. Despite the vast potential usefulness of water in drug discovery and
design, it is often unavailable to academic and industrial design programs. This is often because
drug design groups are not focused on computation and lack the ability or commercial resources
to create high resolution solvation maps. A second major effort in this thesis is addressing this
problem for the pre-eminent drug discovery problem of today, the discovery and design of
therapeutics to treat COVID. To address this, we provide the SARS-CoV-2 solvation repository and
outline how the information can be used to inform drug discovery efforts.
Solvent structures from diffraction data have been compared to waters predicted using
MD simulations48. Geometry-, grid-, and MD simulation-based water prediction programs (GIST49,
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3D-RISM50, SZMAP51,52,53, WaterFLAP54, WaterRank35,36, or WaterMap55,46,38) have been used to
predict waters in the presence or absence of ligands30,56,39,57. WScore and vinaXGB have been
used to improve scoring for protein-ligand docking25,58. In this work, we use Hydration Site
Analysis55,38,59, SSTMap60, and GIST49, which are all MD simulation-based approaches based on
Inhomogeneous Solvation Theory10,11. Hydration Site Analysis is a site-based approach, while
GIST is a grid-based approach. SSTMap software maps structural and thermodynamic water
properties from MD trajectories. Hydration Site Analysis, SSTMap, and GIST can be used to score
ligand-receptor docking, generate or select pharmacophore elements, rationally modify leads,
and to predict locations and orientations of bridging waters for use in ligand-receptor docking.

1.1B SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged and
spread to cause a pandemic of coronavirus disease 2019 (COVID-19). Given the failure to contain
the initial outbreak, the global failure to restrain the pandemic, and the absence of certainty that
vaccines will maintain the necessary widespread use and efficacy, even in the face of new
varaiants, we may need to identify existing drugs or develop new drugs to interrupt COVID-19 at
a critical juncture. A number of targets may be of interest for the development of small molecule
therapeutics for COVID-19: main protease (Mpro, 3CLpro), helicase (Nsp13), endoribonuclease
(Nsp15), and 2’-O-methyltransferase (Nsp10/16) are known viral protein drug targets for SARSCoV-2. Small molecule drugs may target the substrate binding site of M pro, the ADP binding site
of Nsp13, the active site of Nsp15, or the S-adenosylmethionine (SAM) binding site of Nsp16.
SARS-CoV-2 is an especially promising drug target because it is dissimilar to human proteases,
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the main protease sequence and structure are similar to those of other coronaviruses, and prior
lead compounds are already under development for this target 61. At the time of this writing,
Pfizer has received emergency use authorization from the Food and Drug Administration for the
use of nirmatrelvir, a SARS-CoV-2 main protease inhibitor, in combination with ritonavir62.

1.1C Opioids
The nationwide epidemic of opioid overdose deaths has become a major public health
issue. The Centers for Disease Control and Prevention have reported that, since the year 2000,
the rate of deaths from overdoses involving opioids increased by 200% 63. This crisis has
reinvigorated the campaign to develop analgesics that, unlike classical opioid drugs, suffer fewer
serious side effects, such as dependence, tolerance, and respiratory depression, all of which
contribute to the risk of fatal overdose. Computational techniques, such as virtual screening of
chemical libraries against classical opioid receptor structures (CORs), can expedite the
identification of new leads and novel core structures that are likely to bind to a drug target. In
this work, we investigate homologous networks of water molecules found in the orthosteric
binding pockets of classical opioid receptors with a particular focus on the high-resolution and
low-resolution δ-ORs (PDB IDs: 4N6H and 4EJ4, respectively).
The classical opioid receptors (CORs: δ-OR, κ-OR, and µ-OR) feature a high degree of
sequence homology, particularly within the orthosteric binding pocket. They share a 60% amino
acid sequence identity when we include the N-termini and extracellular loops, which confer much
of the opioid receptor subtype selectivity. Between 7-transmembrane (7-TM) regions of µ-OR
and δ-OR, we find 76% homology64. This region includes the structurally similar orthosteric
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binding site. The orthosteric binding sites for µ-OR and δ-OR, in particular, share many common
small molecule ligands that often feature only minor differences in ligand-receptor binding
affinities due to the high degree of structural homology. Opioid receptor function is complex,
particularly given the several opioid receptor subtypes. Currently, the majority of clinically
available painkillers are µ-OR agonists. Despite that µ-OR is the primary target for analgesics, the
κ-OR and δ-OR also regulate analgesia and pain. δ-OR antagonists may be useful in simultaneous
targeting of multiple opioid receptor subtypes.65
Experiments with ligand-receptor docking to a classical opioid receptor using a lowresolution inactive structure of µ-OR (PDB ID: 4DKL) resulted in the discovery of several new
scaffolds unrelated to known opioids and a novel opioid agonist (PZM21) optimized in an attempt
to yield fewer and less severe side effects66,67. Optimization of the chemical structure of the lead
compound involved the introduction of a phenolic hydroxyl to exploit a water-mediated
hydrogen bond between our bridging waters of interest and µH2976.52.
Models of low-resolution x-ray crystal structures of class A G protein-coupled receptors
(GPCRs) sometimes fail to sufficiently resolve electron densities used to identify purported
locations of the oxygen atoms of water molecules in receptor models. The ability to predict
probable locations and orientations of functionally significant waters for low-resolution models
of GPCRs is a practical goal that can improve results of virtual screening. Ligand-receptor docking
enrichment has been improved for adenosine A2A receptor (A2A) by including several waters from
the x-ray crystal structure (A2A, PDB ID: 3EML)68 or waters obtained using molecular dynamics
(MD) simulations (A2A, PDB ID: 4EIY)24. Virtual screening results have been improved also for
kappa-opioid receptor (κ-OR, PDB ID: 4DJH) by including explicit waters for binding affinity
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calculations obtained from MD simulations of κ-OR69, but that procedure involved the use of wscore to calculate binding affinities in order to improve ligand-receptor docking enrichment. Our
study improves docking enrichment against δ-OR using Glide without any alteration to the
standard method for binding affinity calculations (Glide Score) in Maestro.
Since water molecules are important for ligand binding to κ-OR, they might also be
important for ligand binding to other opioid receptors. For our study, we used one highresolution (1.80 Å) and one low-resolution (3.40 Å) δ-OR x-ray crystal structure, 4N6H70 and
4EJ471 respectively. The high-resolution x-ray crystal structure (4N6H) revealed the locations of
water molecules while the low-resolution x-ray crystal structure (4EJ4) did not reveal the
locations of water molecules. The purported waters in this study are present also in x-ray crystal
structure models of other CORs with a resolution better than 2.91 Å. These COR models of x-ray
crystal structures reveal three waters bridging the interactions among the hydroxyl of the
tyrosine-like moiety of each respective ligand and the side chains of the homologous Y 3.33 and
H6.52 for each receptor (δ-OR, PDB ID: 4N6H70; µ-OR, PDB ID: 5C1M72; κ-OR, PDB ID: 4DJH73). Only
two of these water molecules are visible in lower resolution structures (δ-OR, PDB ID: 4RWD74,
µ-OR, PDB ID: 4DKL75) Resolution of electron densities for the oxygen atoms of purported bridging
water molecules were presumably insufficient to place water molecules with confidence for
either of the lowest-resolution CORs (δ-OR, PDB ID: 4RWA74, δ-OR, PDB ID: 4EJ471). The number
of resolved water molecules is apparently correlated with the determined resolution of each xray crystal structure. These receptors are bound to structurally divergent co-crystallized ligands,
though the presence of a tyrosine-like moiety in each ligand remains constant.
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Figure 1. Centroids of resolved oxygen densities. X-ray crystal structure models of classical
opioid receptors (CORs: δ-OR, µ-OR, and κ-OR) reveal centroids of resolved oxygen densities
(red spheres) whose locations might suggest both receptor side-chain contacts and contacts
made with co-crystallized ligands.
10

X-ray crystal structures of classical opioid receptors (PDB IDs: 4N6H 70, 4DKL75, 4DJH73,
4RWA74, 4RWD74, 5C1M72) of sufficiently high resolution to reveal oxygen densities of purported
water molecules suggest that co-crystallized ligands interact with bridging waters that mediate
receptor contact between their respective ligands and the conserved H 6.52 residue. In each case,
water mediates contact between the H6.52 residue of the receptor and the hydroxyl group of the
tyrosine-like moiety of its respective co-crystallized ligand. The ubiquitous presence of bridging
waters across opioid receptor subtypes suggests that these interactions might be important to
receptor function. From a practical perspective, inclusion of these conserved bridging water
molecules might also improve ligand-receptor docking enrichment. The oxygen densities of three
bridging water molecules are visible in the high-resolution (1.80 Å) δ-OR x-ray crystal structure
(Fig 1A, PDB ID: 4N6H)70 but not in the low-resolution (3.40 Å) δ-OR structure (Fig 1B, PDB ID:
4EJ4)71 for which the locations of bridging water molecules were not resolved. Oxygen densities
of three bridging water molecules are visible in the (2.90 Å) κ-OR structure (Fig 1C, PDB ID:
4DJH)73. Oxygen densities of only two bridging water molecules are visible in the (2.80 Å) µ-OR
structure (Fig 1D, PDB ID: 4DKL)75 despite structural homology within the region where we might
expect that a third bridging water molecule would be located.
Orthosteric binding pockets of classical opioid receptors feature conserved residues
(D3.32, Y3.33, K5.39, H6.52), residues that confer ligand-receptor binding selectivity (W6.58, K6.58, E6.58),
and purported oxygen densities that suggest the presence of bridging water molecules (red
spheres). The presence of oxygen densities of purported water molecules roughly correlates with
the resolution of the x-ray crystal structure, as expected. The opioid receptor structures (A) δ-OR
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(PDB ID: 4N6H, 1.80 Å) and (D) κ-OR (PDB ID: 4DJH, 2.90 Å) reveal oxygen densities that correlate
with the apparent presence of three bridging water molecules. The (B) µ-OR (PDB ID: 4DKL, 2.80
Å) x-ray crystal structure model reveals oxygen densities that correlate with two bridging water
molecules and the (B) low-resolution δ-OR (PDB ID: 4EJ4, 3.40 Å) failed to resolve oxygen
densities of water molecules.
Evolutionary conservation of opioid receptor residues Y3.33 and H6.52 (BallesterosWeinstein numbering76) across the CORs suggests that these residues might be important to
opioid receptor function, in general. In x-ray crystal structure models, Y3.33 interacts directly with
co-crystallized ligands but H6.52 does not, however both Y3.33 and H6.52 are adjacent to oxygen
densities and appear to interact with purported bridging water molecules. In all heretofore
known classical opioid receptor x-ray crystal structure models70,71,75,73,74,72 of sufficiently high
resolution, residue H6.52 was observed to interact with a bridging water that mediates ligandreceptor interactions and Y3.33 is observed to be located within hydrogen bonding distance of a
bridging water molecule and an oxygen atom of the receptor-bound ligand. Mutation studies
report that δY129F3.33 or δY129A3.33 mutations reduce the ligand-receptor binding affinities for
some ligands, sometimes dramatically77,78. To our knowledge, no such mutation study is available
for δH2786.52, though one mutation study of µH297A6.52 demonstrated abolished ligand binding
for all ligands tested against the mutant79. A single µY148F3.33 mutant study reported decreased
binding affinities for some ligands, no change in binding affinities for others, and increased
binding affinity for still other ligands80. For κ-OR, the κH291A6.52 mutation lowered ligandreceptor affinity for dynorphin A, but neither κH291A 6.52 nor κH291F6.52 had anything more than
a small effect on the binding affinities of tested ligands. However, κH291A6.52 mutation uniformly
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decreased receptor activation by more than 1.5 orders of magnitude and κH291F 6.52 decreased
potencies up to an order of magnitude, while κH291K6.52 mutation resulted in no detectable
binding by any ligand81. These studies suggest that Y3.33 and H6.52 side chains might have
functional significance for ligand-receptor binding in CORs. Moreover, inclusion of these explicit
water molecules during docking procedures might make contributions to binding affinity
predictions and might therefore be useful to improve results of ligand-receptor docking
enrichment. Given the apparent mediation of ligand-receptor interactions and ubiquitous
presence of these bridging water molecules in higher-resolution opioid receptor x-ray crystal
structures, we investigated the effects of inclusion of these purported bridging water molecules
on ligand-receptor docking enrichment.
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2 Methods
2.1a Protein preparation (opioid receptors)
Opioid receptor starting structures (PDB IDs: 4N6H70, 4EJ471, 4DKL75, 4DJH73, and 5C1M72
were obtained from the Protein Data Bank82 (www.rcsb.org) and prepared using Schrödinger’s
Maestro83. Since we are most interested in the orthosteric binding site, which is situated well
away from the desired deletion, x-ray crystal structure-stabilizing chains or insertions were
deleted: T4 lysozyme insertion residues N1002-Y1161 (4EJ4, 4DKL, and 4DJH), camelid antibody
fragment residues Q3-A127 (5C1M), soluble cytochrome b562 residues A1001-L1106 (4N6H). For
structures with more than one chain, chain A was kept and chain B deleted, except for 6B73 for
which chains B, C, and D were deleted. All heterogeneous groups, except ligands, were deleted.
For 4DKL, the µK233 atom forming the covalent bond with the morphinan antagonist was deleted
and the lysine side chain replaced. The µK233 side chain rotamers were found and the most likely
alternative was selected (24.2%) as it made the expected contact with µE229, then only µK233
was minimized. Following the minimization of µK233, only the morphinan antagonist was
minimized. Then, for all receptors, bond orders were assigned, hydrogen atoms added, disulfide
bonds created, termini capped, and overlaps found. For missing atoms where the backbone was
present and side chains were missing, Schrödinger’s Prime 84 was used to predict side chains.
Alternate positions for amino acid side chains were available for several residues of 4N6H. Only
∂K214 was present within the binding pocket. For ∂K214, we selected the extended side chain
position. For all receptors, the tautomeric state of H6.52 was assigned as HIE. Ionization and
tautomeric states of the ligands were assigned to maximize the number of hydrogen bonds while
minimizing the state penalty as predicted by Epik85. Hydrogen bond assignments were optimized
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using exhaustive sampling, hydrogen atoms of altered species were minimized, and water
orientations were sampled. Structures were minimized to an RMSD of 0.30 Å using an OPLS 2005
force field. For 5C1M, modified residue YCM57 was mutated to the native cysteine (C57) and the
new residue was energy minimized. In each case, when present, waters for use in docking were
retained: 4N6H (HOH 1323, 1324, and 1336) and 4DKL (HOH 718 and 719). Only two bridging
water molecules of interest were resolved in 4DKL. 4DJH features our bridging waters of interest
(HOH 1303, 1307, and 1311), but also contains an additional water bridge near the extracellular
side of the orthosteric binding pocket (HOH 1305 and 1310) that forms an additional hydrogen
bond to JDTic in the x-ray crystal structure model. For 4DJH, additional bridging waters (HOH
1305 and 1310) were retained for all docking structures while the bridging waters of interest
(HOH 1303, 1307, and 1311) were varied in the same manner as for the other systems. Receptor
structure models 4EJ4 and 6B73 contained no resolved bridging waters.

2.1b Protein preparation (SARS CoV-2)
Protein monomer structures were prepared using the Protein Preparation Wizard 86 in
Maestro87 with default settings. ACE and NMA groups were used to cap the protein termini.
Active sites were visually inspected and compared to ligand-bound structures to ensure that
protonation states and conformations were consistent with known ligand-protein interactions.
All proteins were left as-is except for 6YB7, for which side chain rotamers were adjusted so as
not to interfere with the binding of an aligned N3 ligand from 6LU788. His164 was changed from
being protonated in the delta position (HID) to the epsilon position (HIE) to reproduce the known
protein ligand interaction. The protein preparation wizard also suggested two conformations for
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Met166 in 6YB7 and both were used. No changes were made for other proteins. Energy
minimization for hydrogen atoms was then performed in Maestro.
A second set of structure models for SARS-CoV-2 Mpro (PDB IDs: 6YB7 and 6W63) were
manually prepared by one of the authors (McKay). All histidine side chains were assigned as
either HIE or HID given the local environment. All asparagine and glutamine side chains were
examined and found to be in reasonable rotameric states. For these systems, the PARM@FROSST
small molecule extension to ff14SB89 and AM1-BCC90 charges were used for the ligands.

2.2a Molecular dynamics simulations (opioid receptors)
Amber MD simulations were run for 100 ns (100,000 frames) for each receptor (PDB IDs:
4N6H, 4EJ4) with all heavy atoms restrained at 2.5 kcal/mol. 4N6H was run without any ligand
(NTI was deleted from the x-ray crystal structure model) but 4EJ4 was run with NTI in the binding
pocket. In both cases, the centroid of 10,000 frames for each receptor was exported for use in
docking. We used hydration site analysis91,38,92 applied to output from Amber MD simulations to
define hydration sites based on local water densities. Hydration site analysis was conducted on
10,000 frames, which were taken evenly from the 100,000 frame Amber MD simulations. Within
each hydration site, nearest neighbor distances were used to estimate the peak of the position
distribution to define the most probable location of water molecules. Nearest neighbor distances
were also used to estimate the peak of the orientation distribution to define most probable
orientations of water molecules. The predicted locations of water molecules predicted for both
high- and low-resolution δ-OR models (PDB IDs: 4N6H and 4EJ4, respectively) were comparable
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to the locations of oxygen densities found in the high-resolution x-ray crystal structure of δ-OR
(PDB ID: 4N6H).

2.2b Molecular dynamics simulations (SARS-CoV-2)
Molecular dynamics simulations were performed in GPU accelerated AMBER 1693 using
the ff14SB89 force field and the optimal point charge (OPC) model94 of water. Ligand force field
parameters were assigned with the general AMBER force field (GAFF) 95 using the Antechamber
package96 in AmberTools. Antechamber assigns charges, missing bonds, angles, dihedral angles
and Lennard-Jones parameters for each atom. Ligand charges were assigned using AM1-BCC90.
For systems with a co-crystalized ligand, the ligand was removed from the protein, and then the
protein was solvated in a box of OPC water molecules with dimensions that ensured there were
at least 10 Å between any atom of the protein and the box edge. Sodium or chlorine counterions
were added accordingly to neutralize the system. Each system was then energetically minimized
in a two-step process. The first minimization step was performed with 1500 steps of steepest
descent with all protein atoms restrained harmonically using a force constant of 100 kcal/mol·Å2.
For the second minimization step, only main chain heavy atoms were restrained. Following
minimization, the system was heated to 300 K in a 240 ps NVT simulation with the main chain
heavy atoms restrained; the temperature was regulated by Langevin thermostat with collision
frequency of 1 ps. This was followed by a 20 ns NPT simulation with the atom restraints declining
from 100 Kcal/mol·Å2 to 2.5 Kcal/mol·Å2 in the first 10 ns. After that, a 50 ns NPT production
simulation was conducted with the frames saved every 2 ps. In the production phase, the
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temperature was regulated via a Langevin thermostat set to 300 K with a collision frequency of
2 ps. The constant pressure (1 atm) was maintained by isotropic position scaling with a relaxation
time of 0.5 ps.

2.3 GIST
GIST maps were created using the GPU port97 of AmberTools cpptraj-GIST49. Analyses
were performed on the complete 50 ns production trajectory for each system (25000
configurational snapshots). For each system, maps were created in a cubical region with 30 Å
length sides centered on the geometric mean position of the co-crystalized ligand for the pdb
(see Figure 2). The resolution of the grid was 0.5 Å (0.125 Å 3 per voxel). For structures with no
co-crystalized ligand for the pdb entry, a homologous protein with a co-crystalized ligand was
structurally aligned to the pdb structure and the geometric center of that ligand was used to
define the GIST analysis region. In the case of 6JYT, the region was defined for HSA by a partial
set of the residues found in the active site (K288, S289, D374, E375, R567). For the GIST analysis
of 6JYT, the geometric center of ADP from a structurally aligned 2XZL was used as the center of
the box. The ligands used for defining the GIST region for each structure can be found in the
repository.
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Figure 2. The co-crystalized structure of Mpro (cartoon) with ligand N3 from 6LU7. The GIST
analysis was performed in the cubical region shaded in gray.

2.4 Hydration Site Analysis
Hydration Site Analysis (HSA)46 was performed using the publicly available SSTmap code60
with the default settings except for the region analysis which was set to within 10 Å of the ligand
(-d 10). For each system, the analysis was per the first 20 ns (10,000 frames) of the MD production
run for each protein. Briefly, the method analyzes all the water positions from an MD trajectory
and identifies high-density 1 Å radius spherical regions called hydration sites. In each hydration
site, average quantities of the water molecules found in the hydration site are calculated and
provide estimates for the local IST thermodynamic quantities. A number of measures that
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describe the local solvent structure and characterize the hydrogen-bonding environment of the
water in each hydration site are also calculated. These measures can be used to characterize the
enhancement or disruption of local water structure, describe the local enclosure, and describe
the average hydrogen bonding interactions that water has in each hydration site with both its
water neighbors and protein. Full details of the calculations are specified in a previous publication
and the code is available on the github.
We also use newly developed code to determine the most probable orientations for water
molecules in each hydration site. To do this, the orientations of all water molecules in each
hydration site are clustered using a quaternion distance metric and the centroid orientation of
each high-density cluster (generally at least 10% of the population) is recorded. The code and
complete details of the method are in the github.

2.5 Library preparation
GPCR Decoy Database (GDD)98 libraries were prepared using Schrödinger’s Maestro. One
NTI structure was removed from the δ-OR antagonist-specific ligand library because a duplicate
was present (ligands 5484728 and 5497186, both naltrindole (NTI)) leaving 15 active compounds
against 624 decoy ligands. Since NTI was present in both δ-OR x-ray crystal structures and as
already present in the database, no additional ligands were added to the library. JDTic was added
to the GDD κ-specific antagonist library because JDTic was used to crystallize 4DJH and, as such,
is found in the x-ray crystal structure model. The number of active ligands was 24, including JDTic,
and the number of unique decoys was 897. β-funaltrexamine was added to the GDD µ-specific
antagonist library because β-FNA was used to crystallize 4DKL. The number of active ligands was
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28, including β-FNA and the total number of unique decoys was 1,053. Ligand structures were
prepared in Maestro LigPrep99 using OPLS_2005 force field. Possible ionization states at pH 7.0
were generated using Epik100. Ligands were desalted and tautomers generated. A maximum of
one low energy ring conformation was generated per ligand. Only for decoy compounds, all chiral
centers were varied. For known ligands, chiralities were determined from 3D structures. A filter
criterion was applied only to the known ligand libraries (GLL) to remove all structures without
any charged amine.

2.6 Docking
Receptor grids were generated for δ-OR structures with and without explicitly placed
water molecules using Glide101,102. Van der Waals radius scaling values were set at default: a
scaling factor of 1.0 and 0.25 partial charge cutoff. The docking site was generated via ligand
selection. For all receptors, the Y3.33 hydroxyl group was allowed to rotate. Glide HTVS was done
with flexible ligands, nitrogen inversion and ring conformation sampling, penalization of nonplanar amides, and Epik state penalties added to the docking scores. Glide SP used flexible ligand
sampling: nitrogen inversions, ring conformations, and bias sampling of torsions for amides only
(penalization of non-planar conformations). Epik state penalties were added to docking scores.
At most, one pre-minimization pose per ligand was reported. Enrichment reports were generated
using Maestro’s Enrichment Calculator. Top poses were ranked using Impact docking score; only
the top pose for each ligand was selected. Glide extra precision (XP) docking runs were carried
out in the same way as Glide SP docking runs, except the XP docking precision was selected, XP
descriptor information was generated, per-residue interaction scores for residues within 12.0 Å
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of the grid center were written, and a report file was written. Pose viewer files were written to
include the receptor. Glide XP Visualizer was used display Glide XP results in a table of XP terms
for each ligand, to generate 3D visualizations for XP terms, and to selectively analyze individual
and groups of ligands. The XP scoring function of Glide (version) was used:
GScore = 0.05*vdW + 0.15*Coul + Lipo + H bond + Metal + Rewards + RotB + Site
For ligand poses generated by Glide (HTVS, SP, or XP), RMSD scores were calculated using
the benzomorphan core of each ligand. When no benzomorphan core was present, RMSD values
were calculated using the heavy atoms of the ligand co-crystallized with its receptor. To validate
prepared receptor structures, co-crystallized ligands (NTI, β-FNA, and JDTic) were taken from xray crystal structure models (PDB IDs: 4N6H, 4EJ4, 4DKL, and 4DJH) in the RCSB Protein Data Bank
(www.rcsb.org)82, prepared in Maestro, and docked to their respective Maestro-prepared opioid
receptor structures using Glide SP. Locations of water molecules predicted from oxygen densities
found in the x-ray crystal structure models were retained and orientations of water molecules
were predicted using Maestro.
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3 SARS-CoV-2
3.1 Repository contents
While the utility of STM is apparent, there are significant obstacles to widespread use.
Of particular concern is that many existing software packages for characterizing water
properties are commercial and, hence, not available to all and/or they require computational
expertise in molecular dynamics, computer modeling, and statistical mechanics in order to apply.
This set of skills often does not exist in wet chemistry labs whose research is dedicated to
discovering and optimizing new pharmaceutical compounds. We sought to remove these
obstacles and make publicly available solvation thermodynamic and structural maps of SARSCoV-2 targets as a resource to the academic and industrial drug design community to aid in their
pursuit of identifying small molecule treatments for COVID-19. In order to aid in screening and
modification of drugs, we offered a free public repository of solvation thermodynamic maps of
significant small molecule COVID-19 drug targets. Here we present solvation maps of 7 targets
that are likely viable for small molecule modulation. All maps and simulation data are publicly
available on the KurtzmanLab github (github): github.com/KurtzmanLab/COVID19_GIST_HSA.
The contents of the repository are as follows:
Structures 1-5 (SARS-CoV-2 structures)
Main Protease (Mpro, 3CLpro): 6LU788 (2.16 Å), 6YB7 (1.25 Å), 6M03 (2.00 Å), 6Y84 (1.39 Å), 6W63
(2.10 Å). Target the substrate binding site of Mpro.
Structure 6 (SARS-CoV-1 structure)
Helicase (Nsp13): 6JYT103 (2.80 Å). Target (1) the ADP binding site but discourage (2) the nucleic
acids binding site. No SARS-CoV-2 structure exists for this protein.
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Structure 7 (SARS-CoV-2 structure)
Nsp16 (2’-O-methyltransferase, nsp 10/16): 6W4H (1.80 Å). Target the S-adenosylmethionine
(SAM) binding site.
All files with prepared structures, topologies files, and molecular dynamics input and
restart files are provided as well as solvation structural and thermodynamic maps described
below.

3.2 Solvation thermodynamic maps
Inhomogeneous solvation theory (IST)104,10,11 provides the statistical mechanical
framework for the solvation thermodynamic quantities from explicit solvent molecular dynamics
simulations. Here, we use two methods: Grid-based Inhomogeneous Solvation Theory
(GIST)105,106 and Hydration Site Analysis (HSA)46 to localize the IST thermodynamic quantities onto
a three-dimensional grid and onto high density 1 Å radius spherical “hydration sites”, respectively.
These localization approaches both process snapshots of the system configurations generated in
molecular dynamics simulations to estimate local IST thermodynamic quantities including local
energies, entropies, and number densities.

3.3 Grid based solvation maps
The repository contains grid-based solvation maps of calculated IST entropies, energies,
and densities in Data Explorer (dx) format. The dx format enables visualization in standard
graphics packages such as VMD and Pymol. For each target, energetic maps are provided for
water’s interactions with the protein, with other water molecules, and the total interactions of
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the water in each voxel with the system as a whole. GIST provides entropy maps for the total
entropy as well maps that separately include the translational and orientational contributions to
the total entropy. Maps are provided for all of the entropy and energy quantities for both
normalized (per water quantities) and density (per voxel) quantities. A complete list of quantities
can be found in Table 1. Detailed descriptions of these quantities can be found in our prior
work49,106.

Quantity

Description

Units

[a]

TStrans

Translational entropy density

kcal/mol/Å3

[a]

TSorient

Orientational entropy density

kcal/mol/Å3

TSsix

Total entropy density

kcal/mol/Å3

[a]

TStrans

Translational entropy density

kcal/mol/Å3

[a]

TSorient

Orientational entropy density

kcal/mol/Å3

Water-water energy density

kcal/mol/Å3

Solute-water energy density

kcal/mol/Å3

Mean number of water neighbors [c]

molecules

[a]

[a]

Eww

[a]

Esw

Neighbor count

[a] Corresponding normalized quantities also reported [b] Dipole moments are reported as time-averaged x,y, and z,components, along
with the mean overall magnitude. [c] Neighbors are defined as two water molecules with an O-O distance of 3.5Å or less.

Table 1. Key GIST quantities.

3.4 Hydration site solvation maps
For each target, the positions and calculated thermodynamic and structural quantities for
the water in each hydration site are summarized in a space delimited spreadsheet file.
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The same energetic quantities as calculated for GIST (above) are calculated for each hydration
site and reported in per water (normalized) units. Additionally, the HSA data includes a
breakdown of the total energy into contributions from Lennard-Jones, electrostatic, and first
solvation shell water-water interactions.
SSTMap also calculates a number of quantities that are aimed at characterizing the local
environment surrounding each hydration site. These are aimed at better describing local water
structure and the interactions of the water in the hydration site with the protein surface.

Quantity
Nnbr

Description
Average # first shell neighbors

Units
None

Average # water-water hydrogen
NwwHB

None
bonds

NswHB

# solute-water hydrogen bonds

kcal/mol

Average water-water interaction
Enbrww

Kcal/nbr
energy by neighbor
# water-water hydrogen bonds

NwwHB,don

None
donated
# water-water hydrogen bonds

NwwHB,acc

None
accepted
# solute-water hydrogen bonds

NswHB,don

None
donated
# solute-water hydrogen bonds

NswHB,acc

None
accepted
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Fraction of hydrogen-bonded
fwwHB

None
neighbors

Table 2. HSA structural quantities.
Quantities that provide a measure of local water structure include the average number
of first shell neighbors each water has in its first solvation shell, the fraction of these neighbors
to which the hydration site water is hydrogen bonded, and the average energy of interaction with
each neighboring water. When compared to bulk water values, these quantities provide
measures of whether the local water structure is enhanced or frustrated91.
Additional quantities that characterize the interaction of the water in each hydration site
with the protein include: (1) an enclosure parameter that describes how much of the region
around the hydration site is protein and how much is water, (2) the average number of hydrogen
bond donor and acceptor interactions that water molecules found in the hydration site have with
the protein surface, and (3) lists of the protein residues that donate and accept hydrogen bonds
to the water in the hydration site.
A list of thermodynamic and structural quantities can be found in Table 2. A text delimited
spreadsheet file summarizing all calculated water properties is found in the HSA directory for
each protein.
In addition, to facilitate visualization, each HSA directory includes pdb files that feature
(1) the hydration site centers, (2) water molecules located at the center of each hydration site
that have the most probable orientation, and (3) water molecules located at the center of each
hydration site that include all probable orientation clusters.
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4 Potential applications
Solvation thermodynamic mapping has been used in a variety of applications aimed at
aiding the discovery and design of new pharmaceutical compounds. In docking, scoring terms
have been added to explicitly account for solvent displacement upon ligand binding and the
modified docking scoring functions have been used to help improve AUC, pose prediction, and
identify novel binding ligands13,14,25. Solvation maps have also been used to create
pharmacophores15 as well as provide criteria to prioritize the selection of pharmacophore sites42.
Both water thermodynamics and water interactions with protein surfaces have been used to
direct lead modification45,107.
Here, we describe by example several potential applications for the solvation maps
provided in this repository.

4.1 Rational lead modification
The properties of water in and around the binding site may be used to direct the design
of chemical modifications to a lead compound or fragment. The physical principles of this are
that the displacement of thermodynamically unfavorable surface water upon the binding of a
ligand will lead to favorable contributions to the free energy as the water is displaced to the more
thermodynamically favorable environment of bulk biological water. Here, we illustrate how
solvation structural and thermodynamic solvation mapping in this repository can be used to
provide insight into which modifications may lead to boosts in binding affinity.
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Figure 3. Hydration sites superimposed with N3 bound to Mpro (PDB ID: 6LU7). Hydration sites
that are located within 7.5 angstroms of N3 and have highly unfavorable energy (ΔE > 0.5
kcal/mol with respect to neat water) are shown as transparent red spheres. The most probable
water orientation for each hydration site is represented by a water molecule at the center of
each sphere. The protein surface proximal (within 11 Å) to N3 is shown in gray.

The binding site of Mpro features a large number of energetically unfavorable hydration
sites (see Figure 3). Prior work38,39 suggests that the displacement of water from these hydration
sites may be correlated with differences in binding affinities between congeneric pairs of ligands.
Most of the hydration sites identified in Figure 3 are displaced by N3. However, the two leftmost
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sites are not. We will focus on the upper left site, hydration site 7 (HS7), as it has an exceptionally
unfavorable thermodynamic profile.
HS7 occupies a small cleft on the surface of the protein, which is formed by 7 different
residues (28, 143, 119, 26, 118, and 145). The water in this cleft is resolved the crystal structures
of 6LU7, 6W63, 6Y84, and 6YB7. However, this water is not reported in 6M03. The water is highly
enclosed by the protein (81.7%) having slightly less than one (0.96) water neighbor, on average,
in its first solvation shell. Despite the hydration site being highly occupied (84.5% occupancy),
the water is exceptionally unfavorable energetically (+2.6 kcal/mol) and entropically (-TS of 4.45
kcal/mol) by IST estimates. Its low entropy result is based on the water’s highly restricted
translational and orientational motion. The water’s high enclosure in the protein cleft and its
formation of two hydrogen bonds with the protein surface severely restrict the water’s
translational freedom leading to a translational entropic penalty of 2.11 kcals by IST estimates.
The two hydrogen bonds it forms with the protein surface as well as forming a hydrogen bond
82 percent of the time with its water neighbor located above the cleft (HS56), further restrict its
orientational freedom resulting in an entropic penalty of 2.33 kcals/mole.
Despite being on a hydrophilic surface (forming on average 2.00 hydrogen bonds with the
protein), the water in HS7 cannot form a full complement of hydrogen bonds, instead forming
only 2.85 geometric hydrogen bonds on average compared to a bulk OPC water which would
form 3.62. This deficiency of more than three quarters of a hydrogen bond, on average, is a
significant contribution to the unfavorable energetic profile (+2.6 kcals/mole overall) of HS7.
Both the unfavorable IST energy and entropy suggest that displacing this HS7 water could lead to
gains in binding affinity. In order to displace this water, an optimal chemical group must replace
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interactions that the water makes with the protein without disrupting the hydrogen bond
network that the water is making with its neighbors. As the water in HS7 is located in a cleft, any
chemical group would also need to displace its water neighbor (h-bonded water in figure 3). The
optimal chemical group would need to both donate a hydrogen bond to the backbone carbonyl
of Gly143 and accept a hydrogen bond from the backbone amine of Asn119. A hydroxy group
seems ideal for this.
All of the numerical data in the above analysis is located in the HSA summary spread sheet
for 6LU7 (6LU7_apo_flex_hsa_ summary.csv). All the data for the visualizations is likewise located
in the repository.

Figure 4. The most probable orientation of the water in HS7 donates a hydrogen bond (red
dashed line) to the backbone carbonyl of Gly143, accepts a hydrogen bond (blue dashed line)
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from the backbone NH of Asn119, and donates a hydrogen bond to HS56 above the cleft
wherein lies HS7.

4.2 Scoring Solvation Displacement in Docking
Four studies outline how solvation thermodynamic mapping can be used to aid in the
discovery of new leads in docking. The first two of these studies are based on our prior work on
Factor Xa38,39 in which a displaced solvent functional used high energy and high density voxels as
functional inputs to correlate with experimental measurements of differences in binding free
energies between congeneric pairs of ligands. The third docking study 14 by Uehara and Tanaka
instead used a displaced solvent functional with free energetic maps created by GIST as input
whereas the fourth study13 by Balius et al. used the displacement of voxels with high energy
densities as input. The third study showed improvements in pose prediction and enrichment and
the fourth showed only nominal measurable improvements to docking enrichment and pose
prediction, though the method was successfully used to prospectively identify new tightly binding
compounds, including the tightest binding compound to cytochrome c peroxidase. A map
showing related unfavorable and favorable energy density regions for M pro is shown in figure 5.
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Figure 5. Unfavorable and Favorable Solvation Energy Density Map of Mpro. Regions of
unfavorable energy density (Edens > 0.1 kcal/mole/ Å3) and favorable energy density ((Edens > 0.1
kcal/mole/ Å3) are shown in red or blue wireframe, respectively. The predicted score for a
docked ligand would be penalized for displacing water from the favorable blue regions or given
an affinity boost for displacing water from the red regions.
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The GIST maps in this repository provide the data to create the maps used in all three of
the GIST-based studies. Necessary modifications of the provided GIST dx maps (e.g. creating a
free energy density map from the energy and entropy density maps) can be easily created using
the GIST Post-Processing (GISTPP) code provided on the github.

4.3 Pharmacophore Creation
Solvation mapping can be used to generate water-based pharmacophore hypotheses15
and to prioritize ligand- or protein-based pharmacophore sites42. Here we combine several
interesting hydration sites with ligand-based pharmacophore elements.
Three pharmacophore sites were constructed using ligand-protein interactions based on
analyses of co-crystalized ligands found inside the binding sites of SARS-CoV-2 Mpro structures
(PDB ID: 6W63, 6LU7, 6Y2F, 6Y2G, and 6M2N). These ligand-based sites appear as dotted spheres
in Figures 6 and 7.
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Figure 6. Hybrid ligand- and water-based pharmacophore within the binding site of M pro (PDB
ID: 6LU7). The ligand-based sites are shown as dotted spheres and the water-based sites are
shaded spheres. Ligand-based sites have an NH group for donors or an oxygen for acceptors.
The most probable water orientation is found at the center of each water-based
pharmacophore site. Acceptor sites are red and donor sites are blue spheres.

The leftmost ligand-acceptor site (figures 6 & 7) lies inside the oxyanion hole. All five of
the co-crystalized ligands accept a hydrogen bond from the backbone amino group of Gly143
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while three of five (6Y2F, 6Y2G, and 6M2N) also accept a hydrogen bond from Cys146. The
pharmacophore site shown in figure 7 shows both of these interactions. The middle ligand-based
site donates a hydrogen bond to the backbone carbonyl of His164. Ligands from 6W63, 6Y2G and
6Y2F make this contact. The rightmost ligand site, inside the S1 subsite, accepts a hydrogen bond
from the backbone amino group of Glu166. Four of the five (all except 6M2N) co-crystallized
ligands accept a hydrogen bond from this group. Each ligand-based site is proximal to a hydration
site and GIST high-density group of voxels but none have any significant thermodynamic signal
for use in prioritization. These ligand-based sites were chosen by the fact that they were well
conserved across the limited number of structures available with co-crystallized ligands.
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Figure 7. The same hybrid pharmacophore hypothesis as shown in Figure 6, except the
interactions with chemical groups on the surface are shown explicitly. Blue dashed lines show
the pharmacophore sites donation of hydrogen bonds and red dashed lines show acceptation.

We used hydration site analysis to add three additional ligand-based pharmacophores
sites. These sites are shown in shaded spheres in figures 6 and 7. While water-based
pharmacophore sites can be chosen using other criteria (as outlined in Jung et al. 15), here we
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simply chose water-based sites that are energetically unfavorable and categorized them based
on their donor/acceptor interactions with the protein surface.
The first site (on the far right of figures 6 and 7) is from HS9, which primarily accepts a
hydrogen bond from the backbone amino group of residue Thr190 and has an unfavorable energy
of -11.28 kcals/mole (almost 1 kcal above the bulk energy of -12.26 kcals/mole). The second site
HS52 (middle left in Figures 6 & 7) has an energy of -10.46 kcals/mole (1.8 kcals above bulk energy)
and donates a hydrogen bond to Thr26. The third site, HS56 has an energy of -11.69 kcals/mole
(0.57 kcals less favorable than bulk) and donates a hydrogen bond to Thr25.
Together, the conserved ligand sites and the water-based sites create a pharmacophore
hypothesis that can used to screen virtual compound databases.
While we arbitrarily chose three conserved sites from the ligand and three proximal
hydration sites to construct the hypothesis outlined here. This approach allows a drug designer
flexibility to choose ligand and water sites on virtually any solvent exposed surface of the protein,
allowing different regions of the active site or potential allosteric sites to be targeted.
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5 How to access data
All hydration site and GIST data is available on github with a readme.md that details
directory structure and the descriptive file naming convention.
Briefly, each PDB structure has its own subdirectory named after its pdbid. Each pdbid
subdirectory has further subdirectories for simulations with apo or complexed structures and
different protein restraints. Additional subdirectories for each of these include the hydration site
and GIST analyses, as well as the prepared protein input files and Amber MD restart files in case
longer simulations are desired.
All of the above can be found on the github: github.com/KurtzmanLab/COVID19_GIST_HSA

5.1 Code availability
All water analysis code used to produce this data is open-source with extensive
documentation and has been made available for download. These resources, combined with the
provided prepared structures and input files, allow for all the data provided here to be
reproduced.
Three sets of code were used for the water analysis in the repository: SSTMap, GISTcpptraj, and GISTPP. SSTMap was used for hydration site analyses, GIST-cpptraj was used for the
GIST analyses, and GISTPP was used to make numerical manipulations to the GIST dx files. Usage
tutorials and documentation can be found on the SSTMap project page (SSTMap.org) and on the
AMBER website. GIST-cpptraj code is available on the Amber-MD github
https://github.com/Amber-MD
All other code is available on the github:
https://github.com/KurtzmanLab
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6 OPIOID RECEPTORS
6.1 Validation of Structures
Maestro-prepared x-ray crystal structure models of opioid receptors without bridging
waters were validated using ligand-receptor docking (Maestro Glide SP) of co-crystalized ligands.
Docking was also performed on structures that did include purported bridging waters generated
by Maestro from the resolved oxygen densities that are identified as oxygen atoms of water
molecules in the PDB file. Docked ligand poses were measured against the benzomorphan core
structures of NTI or β-FNA, or against all the heavy atoms of JDTic, as these co-crystallized ligands
are present in the x-ray crystal structure models taken from the Protein Data Bank. Docking
without bridging water molecules produced reasonable ligands poses (Table 3) for the four tested
δ-, µ-, and κ-OR structures (PDB IDs: 4N6H and 4EJ4, 4DKL, and 4DJH, respectively). Docking of
co-crystallized ligands in the presence of bridging water molecules also produced reasonable
ligand poses, but sequential inclusion of bridging water molecules also produced incremental
concomitant decreases in Glide Scores (Table 3), which can be expected to improve docking
enrichment. The δ-OR structure (PDB ID: 4EJ4, 3.40 Å) did not resolve oxygen densities due to
the low resolution of the structure. Oxygen densities of some bridging water molecules failed to
resolve and were therefore unavailable for µ-OR (PDB ID: 4DKL, 2.80 Å) and δ-OR (PDB ID: 4EJ4,
3.40 Å).
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Table 3. Ligand poses validate the prepared opioid receptor models and GlideScores reveal a
potential use for predicting bridging waters. Locations and orientations of bridging waters were
generated using Maestro. The low-resolution δ-OR (PDB ID: 4EJ4) x-ray crystal structure model
did not contain resolved oxygen densities, so Maestro could not predict locations and
orientations of purported bridging waters.

Visual inspection of ligand-receptor complexes confirmed that docked ligands reproduced
contacts found in the x-ray crystal structures. Each docked ligand formed a salt bridge (between
a cationic amine of the ligand and the anionic D3.32 side chain) and/or at least one hydrogen bond
between the protonated amine and the D3.32 side chain. Docked ligands formed hydrogen bonds
between a ligand hydroxyl group and the hydroxyl moiety of the conserved Y3.33 residue. Docked
poses also featured π-cation interactions between the protonated amine of the ligand and the
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aromatic ring of the Y3.33 side chain. These validated Maestro-prepared x-ray crystal structure
models of opioid receptors, with and without resolved bridging water molecules, were
subsequently used for docking against decoy libraries.
Two different methods were used to predict the locations and orientations of bridging
water molecules for docking. The first method involved the use of Maestro to predict the
orientations of bridging water molecules whose locations were identified based on the locations
of oxygen densities of purported bridging water molecules found in x-ray crystal structure models
(Maestro waters). This method is limited to instances in which the oxygen densities of water
molecules have been resolved. The second method involved prediction of both the locations and
orientations of bridging water molecules using Hydration Site Analysis (HSA) applied to the
output of explicit water Amber molecular dynamics simulations (Amber MD/HSA waters). This
second method, HSA, is theoretically unlimited as water molecules could be produced for any
structure. But we wonder whether and under what circumstances bridging waters can be located
and orientated, and how effective those bridging waters can be for ligand-receptor docking, if at
all. Here follows a comparison of results from the two methods.

6.2 Locations & Orientations of Bridging Waters
The high-resolution δ-OR (PDB ID: 4N6H, 1.80 Å) was subjected to both methods to
predict locations and orientations of bridging water molecules. Predicted locations of water
molecules from Amber MD/HSA were analogous to the locations of oxygen densities of the
bridging water molecules found in the x-ray structure model. Orientations of water molecules
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predicted using in-house scripts applied to Amber MD simulations were comparable to
orientations of water molecules predicted using Maestro protein preparation (Fig 8). In both
cases, three water molecules were found to bridge interactions among δH278 6.52, δY1293.33, and
δK2145.39. Of the three water molecules of interest, the first donates hydrogen bonds to both the
backbone carbonyl and the ND1 nitrogen δH2786.52 while accepting one hydrogen bond from a
second adjacent water molecule. That second water also donates a hydrogen bond to the
backbone carbonyl of δK2145.39 and accepts a hydrogen bond from the hydroxyl of the tyrosinelike moiety of NTI or another docked ligand with a complementary moiety. The third water
molecule forms hydrogen bonds with the hydroxyl of the tyrosine-like moiety of the ligand and
the side chain hydroxyl of δY1293.33.
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Figure 8. Predicted bridging water locations and orientations for high-resolution δ-OR (PDB ID:
4N6H) and low-resolution δ-OR (PDB ID: 4EJ4). Orientations of bridging waters were predicted
using Maestro for the high-resolution δ-OR (A). Hydration Site Analysis was applied to the
output of Amber MD simulations to predict the locations and orientations of water molecules
for the high-resolution δ-OR (B) and the low-resolution δ-OR (D). Locations of water molecules
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were absent in the PDB file for the low-resolution δ-OR (C). Without locations of the oxygen
atoms of water molecules provided by the PDB file, Maestro is unable to determine the
locations and orientations of water molecules.

Figure 9. An acceptable order for the addition of bridging waters was deduced from clusters 6,
7, 8, 10, and 13 obtained from Amber MD/HSA of the δ-OR (PDB ID: 4N6H). We first dock
without bridging waters (denoted 0), then one bridging water (C6; denoted 1), then two
bridging waters (C6 + C7; denoted 2), then three bridging waters (C6 + C7 + C10; denoted 3).
Analogous waters are found among all classical opioid structures.
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6.3 Sequence of Addition (Docking Waters)
Rather than use a binary option, ligand-receptor docking with or without bridging waters,
we tested the effect (on docking) of the addition of purported bridging waters one at a time. For
this, we deduced an acceptable sequence of addition. We identified a series of water clusters
that, as a coordinated unit, would interact with both the ligand and receptor (clusters C6, C7, C8,
C10, and C13), if a ligand were present and making expected contacts. Of these clusters, C8 is
expected to be displaced by a ligand (Fig 9) and some complimentary ligand moiety, most likely
a hydroxyl, of the ligand that will directly form hydrogen bonds with C7 and C10 while occupying
an appropriate limited amount of space. Of the remaining clusters (C6, C7, C10, and C13), we
asked which clusters formed the most hydrogen bonds to the receptor. Both C6 and C13 form 2
hydrogen bonds to the receptor. However, C6 spends more time forming two hydrogen bonds
with the receptor. This suggests that C6 forms a more stable and persistent interaction with the
receptor than C13. Cluster 6 (C6) is also more rotationally restricted than C13. We have two
options for the addition sequence: (a) C6 > C7 > C10 > C13, or (b) C13 > C10 > C7 > C6. Since C6
spends more time with the most hydrogen bonds, is rotationally restricted, and therefore likely
forms the most stable interactions with the receptor, we started with C6 and used the sequence:
C6 > C7 > C10 > C13. However, C13 does not form hydrogen bonds directly with the receptor, so
it was excluded from the sequence for the sake of simplicity. The final sequence for the addition
of bridging waters: no waters > C6 > C6 + C7 > C6 + C7 + C10. Docking without waters is therefore
designated as “0” or “no waters”, docking to C6 is “1 water”, docking to C6 and C7 is “2 waters”,
and docking to C6 and C7 and C10 is “3 waters.” Analogous bridging waters are found among all
classical opioid receptors and were added using in that sequence.
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6.4 Baseline Data for Docking to Bridging Waters
One might ask whether bridging waters are useful for docking to the classical opioid
receptors, in general, or whether they are useful only for the δ-OR. Moreover, we should want
to establish a baseline for the comparison of docking results using bridging water molecules
obtained using Amber MD/HSA. For this, we should use docking results obtained in another
manner, preferably one that uses x-ray crystallography data to determine the locations of water
molecules. In order to suggest an answer to the first question and produce reference data for the
second, we ran Glide HTVS and Glide SP docking runs of µ-OR and κ-OR antagonist libraries
against the inactive conformations of the µ-OR and κ-OR, respectively. We used Maestro to
predict the locations of bridging water molecules based on purported oxygen densities obtained
from µ-OR and κ-OR opioid receptor x-ray crystal structure models taken from the Protein Data
Bank (PDB IDs: 4DKL and 4DJH). Orientations of purported bridging water molecules were
predicted using Maestro protein preparation. And the resulting bridging water molecules were
used for docking. The baseline data appears below. The resolution of the µ-OR (PDB ID: 4DKL)
was too low for the identification of the location of the third bridging water molecule. To remedy
this, the high-resolution δ-OR was aligned to the µ-OR and the water molecule was added to µOR for purposes of obtaining a baseline, with obvious qualification.

47

Figure 10. Inclusion of Maestro-obtained bridging water molecules during ligand-receptor
docking of µ-OR and κ-OR antagonist libraries (GLL) and structurally similar decoys (GDD)
against inactive µ-OR (PDB ID: 4DKL) and inactive κ-OR (PDB ID: 4DJH), respectively, improves
enrichment of known µ-OR and κ-OR antagonists when compared to docking without waters.
Enrichment curves and AUC values for ligand-receptor docking of κ-OR and µ-OR antagonists
against the κ-OR (A, B) and µ-OR (C, D), respectively, using water locations taken from x-ray
crystal structures models and water orientations predicted using Maestro. Inclusion of bridging
waters during ligand-receptor docking improves early enrichment and AUC values using Glide
HTVS (A, C) or Glide SP (B, D) compared to docking without bridging waters.
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Enrichment curves and AUC values reveal overall improvements when docking κ-OR and
µ-OR antagonist libraries (GLL) and their respective structurally similar decoy databases (GDD) to
a series of receptor structures first without waters and then docking to structures sequentially
each time with the addition of a bridging water molecule (structure plus 0 waters, 1 water, 2
waters, and then 3 waters). In each case, using either Glide HTVS or SP, for both κ-OR and µ-OR,
we observe a concomitant decrease in GScores and an increase in AUC values with the addition
of each bridging water molecule.

Figure 11. Inclusion of Maestro-obtained bridging waters during ligand-receptor docking of µOR and κ-OR antagonists (GLL library) against inactive µ-OR (PDB ID: 4DKL) and inactive κ-OR
(PDB ID: 4DJH) improves BedROC and RIE values. BedROC and RIE were used to measure early
recognition of known active compounds for the κ-OR and µ-OR antagonist GPCR Ligand
Libraries (GLL) and structurally similar decoys (GDD) docked to inactive κ-OR and µ-OR,
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respectively. The inclusion of bridging water locations obtained from the x-ray crystal structure
models with orientations predicted by Maestro improved early recognition of known active
compounds. BedROC (α = 8.0, α = 20.0) and RIE values also show concomitant increases with
the sequential addition of bridging waters obtained using locations of bridging waters from
oxygen densities in x-ray crystal structure models and with the orientations of water molecules
predicted using Maestro.
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Figure 12. Inclusion of Maestro-obtained bridging water molecules during ligand-receptor
docking of known µ-OR and κ-OR antagonists (GLL library) and structurally similar decoys (GDD
Library) to inactive µ-OR (PDB ID: 4DKL) and inactive κ-OR (PDB ID: 4DJH) improves enrichment
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factors. (A) Enrichment factors improved with the inclusion of bridging waters (obtained using
Maestro) for docking of the µ-OR and - antagonist GPCR Ligand Libraries (GLL) and structurally
similar decoys (GDD Library) to µ-OR (PDB ID: 4DKL) and κ-OR (PDB ID: 4DJH), respectively,
using Glide HTVS or SP. The most significant increases to enrichment factors were obtained for
the top 1 or 2% of screened ligands. Ligand-receptor docking output was post-processed using
a sorting script (B-E) with a cutoff based on the sum of the changes of GScores across four
docking runs (0, 1, 2, and 3 waters). Ligands whose ΣΔGScores fell below the cutoff were
removed. Equivalent enrichment factors were calculated when 1 or 2% of the combined (GLL
and GDD) library remained. The post-processing script was applied to output from docking
using Glide HTVS (B, C) or Glide SP (D, E) with and without bridging waters against inactive µOR (B, D) or inactive κ-OR (C, E).

Early enrichment is of primary interest when searching large libraries of chemical
structures in search of new compounds, so we attach special weight to enrichment factors. Early
enrichment factors improved for the top 1-2% of ligands with the addition of bridging water
molecules, though the improvement was not present in all cases (Fig 12). Enrichment did not
improve for κ-OR using Glide SP alone. However, the sorting script applied to output from the
GlideSP docking run did improve the “equivalent enrichment factor.” In all other cases, using
Glide HTVS and Glide SP, enrichment factors improved with the addition of water molecules,
particularly for the top 1-2% of hits. However, in these cases, the sorting script did not improve
the “equivalent enrichment factor.”
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6.4 The N-Terminus Problem
Analgesic action tends to operate through µ-ORs and, as such, these are the primary
targets for the development of novel painkillers, though other opioid receptor subtypes should
not be excluded from investigation. We used the µ-OR agonist library (GLL) and a library of
structurally similar decoys (GDD) against the active conformation of the high-resolution µ-OR
(2.10 Å, PDB ID: 5C1M) to see whether the inclusion of bridging waters would improve ligandreceptor docking enrichment. The active conformation of the µ-OR features the N-terminal
extending into the orthosteric binding pocket to interact directly with the bound ligand found in
the x-ray crystal structure model. As a consequence, we docked to the receptor in two states,
with or without the N-terminus. For structures without the N-terminus, the N-terminus was
deleted, and the end capped.
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Figure 13. Inclusion of Maestro-obtained water molecules during ligand-receptor docking
(Glide SP) against the active conformation of high-resolution µ-OR (2.10 Å, PDB ID: 5C1M)
improves enrichment of µ-OR agonists (GLL) over structurally similar decoys (GDD) compared
to docking without waters. Enrichment curves and AUC values for docking of µ-OR agonists
against the high-resolution µ-OR (PDB ID: 5C1M, 2.10 Å) using water locations taken from xray crystal structures models and water orientations predicted using Maestro.

Enrichment curves and AUC values reveal some improvement to overall enrichment in
either case, docking with or without the µ-OR N-terminus. Docking in the presence of the Nterminus diminishes early enrichment of known actives (Fig 13 A), while docking without the Nterminus (Fig 13 B) produces greater overall improvements, particularly when docking in the
presence of three bridging waters using Maestro to locate the oxygen atoms of waters using
oxygen densities and then predict the orientations of the bridging waters. However, early
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enrichment values: BedROC, RIE and EFs are weak (Fig 14). For screening purposes, early
enrichment is more important than performance over the entirety of the library.

Figure 14. BedROC and RIE values for the µ-OR agonist library (GLL) and structurally similar
decoys (GDD) docked to the active conformation of the high-resolution µ-OR (2.10 Å, PDB ID:
5C1M). The increase of BedROC and RIE values signals marginal improvements to early
enrichment with the inclusion of bridging waters. Removal of the N-terminus diminishes early
enrichment, but the inclusion of bridging water molecules has a greater cumulative effect in
the absence of the N-terminal at α = 8.0 and somewhat less improvement for the earliest hits
at α = 20.0.
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Figure 15. Inclusion of Maestro-obtained bridging water molecules during ligand-receptor
docking of the µ-OR agonist (GLL library) and structurally similar decoys (GDD Library) to the
high-resolution active µ-OR (PDB ID: 5C1M) and improves enrichment factors. Inclusion of
water molecules produced (A) insignificant to marginal improvements to early enrichment with
or without the presence of the N-terminus. The sorting script (B, C) reasonably improved
“equivalent enrichment” when docking without the N-terminus (C).
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Enrichment factors (Fig 15) showed marginal improvement when docking the µ-OR
agonist library (GLL) and structurally similar decoys (GDD) to the active conformation of the highresolution µ-OR (2.10 Å, PDB ID: 5C1M) in the presence of bridging waters obtained using
Maestro. Ligand-receptor docking without the N-terminal caused enrichment to decline but,
when three bridging waters were included, enrichment improved and somewhat exceeded
enrichment with bridging waters and the N-terminus in place. Use of the sorting script enabled
us to achieve an improved “equivalent enrichment” that performed better than docking with or
without bridging water molecules, and with or without the N-terminus.
Given the weak performance of ligand-receptor docking enrichment using Maestro
waters, it was worthwhile to test how well we might be able to enrich µ-OR agonists using the
inactive conformations of the low-resolution δ-OR (PDB ID: 4EJ4) and the high-resolution δ-OR
(PDB ID: 4N6H).
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6.5 High-resolution delta-OR: ‘Maestro waters’ vs. ‘HSA waters’
6.5.1 Enrichment Curves and AUC
Docking results for δ-OR antagonists (GPCR Ligand Library) and decoys (GPCR Decoy
Database) against the high-resolution δ-OR (PDB ID: 4N6H) including water locations and
orientations predicted using HSA applied to output from Amber MD simulations were compared
to docking results for the high-resolution δ-OR including waters predicted by Maestro.
Enrichment curves for δ-OR antagonists docked against the high-resolution δ-OR (Fig 16) reveal
that, in all cases (using either Glide HTVS or Glide SP), inclusion of bridging waters improved
ligand-receptor docking enrichment when compared to docking without bridging water
molecules. Area under the curve (AUC) calculations show improvements from ‘fail’ (50-60) or
‘poor’ (60-70) when docking without bridging waters, to ‘fair’ (70-80) when docking with bridging
waters. Increasing AUC values, with the addition of bridging waters, describe overall
improvement to docking enrichment but we are most interested in improvements to ligandreceptor docking enrichment to the top 1-2% of the screened ligand library because drug
discovery efforts often involve screening of large libraries. Inclusion of bridging water molecules
during ligand-receptor docking does tend to increase the probability of active compounds being
ranked earlier than decoy compounds. However, AUC values are not a good metric to evaluate
early recognition of active compounds.
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Figure 16. Inclusion of Maestro-obtained or Amber MD/HSA-obtained bridging waters during
ligand-receptor docking against the high-resolution inactive δ-OR (PDB ID: 4N6H) improves
enrichment of known δ-OR antagonists from a rigorous library of structurally similar decoys
(GDD Library) when compared to docking without waters. Enrichment curves and AUC values
for ligand-receptor docking of δ-OR antagonists against the high-resolution δ-OR (PDB ID:
4N6H, 1.8 Å) using water locations taken from x-ray crystal structures models and water
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orientations predicted using Maestro (A, C) or water locations and orientations predicted using
Hydration Site Analysis applied to output from Amber MD simulations (B, D). Inclusion of
bridging waters during ligand-receptor docking improves early enrichment and AUC values
using Glide HTVS (A, B) or Glide SP (C, D) compared to docking without bridging waters.

6.5.2 BedROC and RIE
Increasing the α variable in BedROC calculations shifts emphasis to earlier hits. Using α =
20.0, BedROC is modulated to emphasize the first 8% of the top-ranked molecules to account for
80% of the score. The ratio of 15 active ligands to total ligands, including 624 structurally similar
decoys, for the δ-OR antagonist library is 0.023 (n/N = 15/639). Tuning parameters (α) were
therefore set to 20.0 and 8.0, and were used to measure the probability that an active compound
would be ranked before a randomly selected compound (n/N*α << 1 for either value). BedROC
values indicate that inclusion of bridging water molecules during ligand-receptor docking
improves early recognition of active compounds in δ-OR antagonist library (GLL) and decoy library
(GDD) docked against the high-resolution δ-OR (Fig 17). Similar trends were obtained using α =
8.0 for BedROC calculations. Robust initial enhancement (RIE) results revealed increasing RIE
values that support results from BedROC calculations that describe improved early recognition
of active compounds.
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Figure 17. Inclusion of Maestro- or HSA-obtained bridging waters during ligand-receptor
docking of δ-OR antagonists (GLL library) and GPCR decoy database (GDD) against the highresolution inactive δ-OR (PDB ID: 4N6H) improves BedROC and robust initial enhancement (RIE)
values. BedROC and robust initial enhancement (RIE) were used to measure early recognition
of known active compounds for the δ-OR antagonist GPCR Ligand Library and structurally
similar decoys docked to the high-resolution δ-OR structure (PDB ID: 4N6H). The inclusion of
bridging waters improved early recognition of known active compounds. Inclusion of waters
obtained using Amber MD/HSA performed as well as inclusion of water locations obtained
from the PDB (4N6H) with orientations predicted by Maestro.
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6.5.3 Enrichment Factors
Enrichment factors (EF) with respect to N% sample size measured improvements to
ligand-receptor docking enrichment for the top 1, 2, 5, and 10% of the screened δ-OR antagonist
library. In every case, enrichment factors increased with the inclusion of water molecules during
ligand-receptor docking relative to enrichment factors obtained from docking to the highresolution δ-OR without bridging water molecules (Fig 18). The effect of the inclusion of water
molecules was most pronounced for the top 1% or 2% of screened ligands, particularly with the
inclusion of several bridging water molecules.

Figure 18. Inclusion of Maestro- or HSA-obtained water molecules during ligand-receptor
docking of known δ-OR antagonists (GLL) to the high-resolution inactive δ-OR (PDB ID: 4N6H)
improves enrichment factors. (A) Enrichment factors improved with the inclusion of bridging
waters (obtained using Maestro or Amber MD/HSA) for docking of the δ-OR antagonist (GLL
library) and structurally similar decoys (GDD library) to the high-resolution δ-OR (PDB ID: 4N6H)
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using Glide HTVS or Glide SP. The most significant increases to enrichment factors were
obtained for the top 1 or 2% of screened ligands.

6.5.4 Relative GScores
Most known active δ-OR antagonists (GLL library) enjoyed decreasing GScores (Fig 19)
with the inclusion of bridging waters and most structurally similar decoys (GDD library) suffered
increasing GScores with the inclusion of bridging waters as revealed in GScore plots for ligandreceptor docking using Glide HTVS (A, B) or Glide SP (C, D) and the δ-OR antagonist library with
structurally similar decoys from the GPCR Ligand Library (GLL) against the high-resolution δ-OR
(PDB ID: 4N6H). For all GScore plots (A-D), red coordinates represent known active ligands and
black coordinates represent structurally similar decoys. GScore plots are shown for water
locations and orientations obtained using (A, C) Maestro waters or (B, D) Amber MD/HSA waters.
For the high-resolution δ-OR, improvements to docked ligand rankings of active compounds, with
the inclusion of bridging waters during docking, were a consequence of decreasing GScores for
known active δ-OR antagonists and increasing GScores for structurally similar decoys (Fig 19).
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Figure 19. Relative GScores from docking ‘without bridging waters’ versus docking ‘with 3
bridging waters’ of known δ-OR antagonists (GLL) and decoys (GDD) against the high-resolution
δ-OR (PDB ID: 4N6H) using Glide HTVS or Glide SP. GScore plots for ligand-receptor docking
using Glide HTVS (A, B) or Glide SP (C, D) and the δ-OR antagonist library with structurally
similar decoys. For all GScore plots (A-D), red coordinates represent known active ligands and
black coordinates represent structurally similar decoys. GScore plots are shown for water
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locations and orientations obtained using (A, C) Maestro waters or (B, D) Amber MD/HSA
waters.

6.5.5 Ligands and Core Structures
For the high-resolution δ-OR with locations and orientations of waters obtained using
Maestro, using either Glide HTVS or Glide SP, ligand-receptor docking enrichment of known
actives (Fig 20) containing a benzomorphan core (Fig 21) and tyrosine-like moiety generally
improved with the inclusion of water molecules (8/15 known actives). Several ligands
(pentazocine (CID 9669), pimozide (CID 16362), levorphanol (CID 5462348), and naltrexone (CID
4428)) enriched above 10% with the inclusion of Maestro waters only for Glide HTVS (1/15 known
actives) or Glide SP (3/15 known actives), but not both. Several ligands (N,N-Diethyl-N'-(2methoxyacridine-9-yl)-1,4-pentanediamine (CID 408117), bremazocine (CID 1223), and lAmidone hydrochloride (CID 22266)) failed to enrich above 10% using either Glide HTVS or Glide
SP (3/15 known actives). Ligands without a tyrosine-like moiety (pimozide (CID 16362), l-Amidone
hydrochloride (CID 22266), and N,N-Diethyl-N'-(2-methoxyacridine-9-yl)-1,4-pentanediamine)
(CID 408117)) failed to enrich for either Glide HTVS or Glide SP, except pimozide (CID 16362),
which was enriched above the top 10% for the Glide SP run. A similar result was obtained for
ligand-receptor docking to the high-resolution δ-OR with the inclusion of bridging water molecule
locations and orientations obtained using Amber MD/HSA. Most ligands containing a
benzomorphan core and tyrosine-like moiety were enriched above the top 10% for both Glide
HTVS and Glide SP (7/15 known actives). The enrichment of two known actives (nalbuphine (CID
5311304) and buprenorphine (CID 40400)) improved only for Glide HTVS (1 known active) or
Glide SP (1 known active), but not for both. The remaining ligands failed to enrich above the top
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10% for either Glide HTVS or Glide SP (6/15 known actives), whether they contained a tyrosinelike moiety (pentazocine (CID 9669), bremazocine (CID 1223), and naltrexone (CID 4428) or did
not contain a tyrosine-like moiety (pimozide (CID 16362), N,N-Diethyl-N'-(2-methoxyacridine-9yl)-1,4-pentanediamine (CID 408117), and l-Amidone hydrochloride (CID 22266)).

Figure 20. Known δ-OR antagonists (GLL library) with tyrosine-like moieties highlighted in red
and labeled with the PubChem Compound ID (CID). Chemical structures of known active δ-OR
antagonists in the GPCR Ligand Library used for docking against high-resolution δ-OR (PDB ID:
4N6H) and low-resolution δ-OR (PDB ID 4EJ4). Each structural region drawn in red is a tyrosinelike moiety that comprises a part of the benzomorphan core. Ligands pimozide (CID 16362),
N,N-Diethyl-N'-(2-methoxyacridine-9-yl)-1,4-pentanediamine (CID 408117), and l-Amidone
hydrochloride (CID 22266) contain neither a benzomorphan core nor a tyrosine-like moiety.
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Figure 21. Chemical structure of the benzomorphan core.

Figure 22. Chemical structure of tyrosine.

Taken together, for all ligand-receptor docking runs using Glide (HTVS or SP) and δ-OR
antagonists (GLL) with structurally similar decoys (GDD) against the high-resolution δ-OR (PDB
ID: 4N6H), including bridging waters (from either Maestro or Amber MD/HSA), all known actives
that enriched above the top 2% (8/15 known actives) contained a benzomorphan core and a
tyrosine-like moiety with a hydroxyl group that formed hydrogen bonds with the bridging waters.
Additional known actives buprenorphine (CID 40400) and quadazocine (CID 115077) each contain
a benzomorphan core and tyrosine-like moiety, enjoyed decreasing GScores with the inclusion of
bridging waters, and enriched to a maximum of 3.44% (0.826 Å) and 3.29% (0.491 Å),
respectively. The known actives, which enjoyed decreasing GScores with the addition of bridging
waters and improvements to ligand-receptor docking enrichment, featured a benzomorphan
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core with a tyrosine-like moiety that formed hydrogen bonds with bridging waters. The remaining
known actives, naltrexone (CID 4428) and bremazocine (CID 1223), that contain a benzomorphan
core and tyrosine-like moiety enjoyed decreasing GScores and improved enrichment to 5.66%
(RMSD 2.927 Å) and 26.29% (RMSD 2.741 Å), respectively. However, the ligand ketone of
naltrexone (CID 4428) unexpectedly interacted with bridging waters and the tyrosine-like
hydroxyl of bremazocine (CID 1223) interacted with a single bridging water while, in each case,
measurements reveal deviations from the expected ligand poses as measured against the
benzomorphan core of co-crystallized NTI. Thus, the appearance of improvements to ligandreceptor docking for known actives naltrexone (CID 4428) and bremazocine (CID 1223) were
unlikely due to any improvement in the docking method. Taken together, 10/12 known actives
(all known actives enriched above 5%) with a benzomorphan core enjoyed decreased GScores,
improved ligand-receptor docking enrichment, reasonable ligand poses (RMSD << 1.00 Å) and
were observed to interact with the included bridging waters via the hydroxyl group of a tyrosinelike moiety. For the δ-OR antagonist ligand library, no ligand without a benzomorphan core (3/15)
was enriched above 5%. Due to the small sample size, this is insufficient to eliminate the
possibility that ligands with other cores are likely to be enriched.

6.5.6 GScore Contributions
δ-OR antagonists (GLL) with structurally similar decoys (GDD) were run against the highresolution δ-OR, with and without Maestro bridging waters, using Glide XP. Inclusion of bridging
waters produced consistent effects on terms included for calculation of GScores (Fig 23). The
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inclusion of Maestro bridging waters produced decreasing GScores for most known δ-OR
antagonists (GLL) that were enriched above 10% with or without the inclusion of waters (Fig 23).
We wanted to know which terms contributed favorably to the decreasing Glide Scores
(thereby improving docking enrichment) when docking in the presence of Maestro waters. Glide
XP was used to dock known δ-OR antagonists (GLL) against the high-resolution δ-OR (PDB ID:
4N6H) with or without three bridging waters (Maestro waters). Each GScore was broken down
into contributing terms: hydrogen bonds (kJ/mol), electrostatics (kJ/mol), and van der Waals
interactions (kJ/mol). The a*Van der Waals term unfavorably increased GScores with the addition
of water molecules, which did not improve ligand-receptor docking enrichment. However, the
b*Coul and Hbond terms did contribute to the decrease in GScores to improve docking
enrichment.
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Figure 23. Contributions to GScores when docking the δ-OR antagonist library (GLL) to the highresolution δ-OR (PDB ID: 4N6H) in the presence of Maestro waters. HBond and Coulomb terms
correlate with the favorable changes to GScores when docking in the presence of Maestro
waters. Known actives enriched above 10% (using Glide SP) were docked here using Glide XP
to obtain values for terms that comprise the GScores.

Changes in the hydrogen bond term and the Coulomb term correlate with decreasing
GScores when docking known δ-OR antagonists (GLL) to the high-resolution δ-OR (PDB ID: 4N6H)
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in the presence of Amber MD/HSA waters versus docking without waters. Results suggest that
the presence of water contributes to GScores of enriched actives via hydrogen bonding and
electrostatic interactions (Fig 24).

Figure 24. Contributions to GScores when docking the δ-OR antagonist library (GLL) to the highresolution δ-OR (PDB ID: 4N6H) in the presence of Amber MD/HSA bridging waters. HBond and
Coulomb terms correlate with the favorable changes to GScores when docking in the presence
of Maestro waters. Known actives enriched above 10% (using Glide SP) were docked here using
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Glide XP to obtain values for terms that comprise the GScores. For the Hbond term, several
values overlap, thus only six data points.

HBond and Coulomb terms correlate with changes in GScores when docking in the
presence of Amber MD/HSA waters. Known actives enriched above 10% using Glide SP were
docked using Glide XP to obtain values for terms that comprise the GScores. Changes in the
hydrogen bond term and the Coulomb term correlate with decreasing GScores when docking
known δ-OR antagonists (GLL) to the high-resolution δ-OR (PDB ID: 4N6H) in the presence of
Amber MD/HSA waters versus docking without waters. As found in the analysis of GScores
obtained from docking to Maestro bridging waters, results suggest that the presence of water
contributes to GScores of enriched actives via hydrogen bonding and electrostatic interactions,
and that Van der Waals interaction detract from the GScore.

6.5.7 Ligand Sorting Script and “Equivalent Enrichment Factor”
Ligands docked to opioid receptors tend to produce good poses (RMSD < 2.0 Å) even
without bridging waters and, in the presence of bridging waters, these ligands continue to dock
with a similar pose (RMSD < 2.0 Å) but also form additional hydrogen bonds and electrostatic
interactions with the included bridging water molecules. The inclusion of bridging waters and
resultant ligand interactions lead to decreases in GScores, which can be helpful to improve ligandreceptor docking enrichment. We used a script to see whether the incremental changes in
GScores with the successive addition of bridging waters, followed by docking in each case, could
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be used to further enrich active ligands based on docking results from four runs: docking to 0
waters, 1 water, 2 waters, and 3 waters. We docked libraries of ligands to the high-resolution δOR without waters and then, separately, docked the ligands to the receptor with one water, and
then with two waters, and then with three bridging waters. Docking results were obtained for
ligand-receptor docking to 0, 1, 2, or 3 bridging waters. The docking output was sorted into lists
of successfully docked ligands, including the predicted GScore for each docked ligand for each
case (0, 1, 2, or 3 waters). We retained only the ligands and structurally similar decoys that
successfully docked to all four receptor and bridging water combinations. Therefore, a total of
four GScores were found for each remaining ligand, with one GScore for each situation docking
to the receptor and 0, 1, 2, or 3 bridging waters.
For any given ligand, if the sequential addition of waters led to a concomitant decrease in
GScore every time a bridging water molecule was added (0 to 1, 1 to 2, and 2 to 3 waters) before
a docking run, the ligand was kept. If the sequential addition of water in any case did not change
the GScore or led to an increase in GScore, that ligand was removed from the list.
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Figure 25. Inclusion of Maestro- or HSA-obtained bridging waters during ligand-receptor
docking of known δ-OR antagonists (GLL library) and structurally similar decoys (GDD Library)
to the inactive high-resolution δ-OR (PDB ID: 4N6H) improves enrichment factors. (A)
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Enrichment factors for the top 1, 2, 5, and 10% of docked (HTVS and SP) δ-OR antagonists (GLL)
and decoys (GDD) for the high-resolution δ-OR (PDB ID: 4N6H). The most significant increases
to enrichment factors were obtained for the top 1 or 2% of screened ligands. Ligand-receptor
docking output was post-processed using a sorting script (B-E) with a cutoff based on the sum
of the changes of GScores across four docking runs (0, 1, 2, and 3 waters). Ligands whose
ΣΔGScores fell below the cutoff were removed. Equivalent enrichment factors were calculated
when 1 or 2% of the combined (GLL and GDD) library remained. The post-processing script was
applied to output from docking using Glide HTVS (B, C) or Glide SP (D, E), and with Maestro
bridging waters (B, D) or with Amber MD/HSA bridging waters (C, E) against inactive highresolution δ-OR.

Then a ΣGScore (kJ/mol) cutoff was applied to the remaining list of successfully docked
ligands whose GScores decreased with the addition of each bridging water molecule. For each
ligand, we obtained the ΣGScores (kJ/mol) across all four cases. We tested a range of ΣGScore
cutoffs from -0.50 to -1.50 kJ/mol, decreasing at -0.05 kJ/mol increments across the full range of
cutoff values. If the value of the ΣGScores (kJ/mol) was more negative than the cutoff, we kept
the ligand. If the value of the ΣGScores (kJ/mol) was more positive than the cutoff, the ligand
was removed from the list. The ‘remaining actives’ (Fig 25) are known active ligands whose
GScores decreased each time a bridging water molecule was added before docking and whose
ΣGScores (kJ/mol) was more negative than the cutoff. Actives whose GScores did not decrease
with every addition of bridging water were removed from the docking list and the remaining
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actives are given as a percentage of the total number of known actives. The ‘decoys removed’
are decoys removed from the docking list because their GScores did not decrease with the
addition of each bridging water molecules or the ΣGScores (kJ/mol) was lower than the cutoff.
These ‘remaining actives’ and ‘decoys removed’ are reported at each incremental cutoff. Finally,
we calculated a so-called “equivalent enrichment factor” to compare the resulting enrichment
from this sorting to the enrichment factors obtained only from Maestro docking. We calculated
the “equivalent enrichment factor” using:
𝐸𝐹1% = {𝐿𝑖𝑔𝑎𝑛𝑑𝑠𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 /𝑁1% }/{𝐴𝑐𝑡𝑖𝑣𝑒𝑠𝑡𝑜𝑡𝑎𝑙 /𝑁𝑡𝑜𝑡𝑎𝑙 }
𝐸𝐹2% = {𝐿𝑖𝑔𝑎𝑛𝑑𝑠𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 /𝑁2% }/{𝐴𝑐𝑡𝑖𝑣𝑒𝑠𝑡𝑜𝑡𝑎𝑙 /𝑁𝑡𝑜𝑡𝑎𝑙 }
In each case, the “equivalent enrichment factor” was calculated for the cutoff at which 1%
or 2% of the combined library remained after removal of known actives and decoys in an
incremental fashion.

6.5.8 Ligand Cores and GScores
For the Glide HTVS run of the δ-OR antagonist library and structurally similar decoy
database library (GLL and GDD) against the inactive conformation of the high-resolution δ-OR
(PDB ID: 4N6H), a whisker plot was made (Fig 26) for known active ligands to reveal the fate of
actives with a benzomorphan core and known superior ligand pose (red, RMSD < 2.0 Å),
benzomorphan core and inferior ligand pose (black, RMSD > 2.0 Å), and ligands without a
benzomorphan core (green). Ligands with benzomorphan cores were preferentially enriched,
which is unsurprising since the co-crystallized ligand contains a benzomorphan core. Given the
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high GScores, ligands without benzomorphan cores failed to enrich using HTVS. The postprocessing script also failed to enrich ligands without benzomorphan cores into the top 1% or
2%.

Figure 26. Whisker plot of GScores from docking results using Glide HTVS with δ-OR antagonist
libraries (GLL) and decoys (GDD) against the inactive conformation of the high-resolution δ-OR
(PDB ID: 4N6H), docked with or without Amber MD/HSA bridging waters, including results from
the GScore selection script. (A, B) GScores for successfully docked ligands (RMSD < 2.0 Å, red)
containing a benzomorphan core, unsuccessfully docked ligands (RMSD > 2.0 Å, black)
containing a benzomorphan core, and ligands containing no benzomorphan core (green). (B)
The top 1% or 2% of ligands identified using the GScore selection script.
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Figure 27. Whisker plot of GScores from docking results using Glide SP with δ-OR antagonist
libraries (GLL) and decoys (GDD) against the inactive conformation of the high-resolution δ-OR
(PDB ID: 4N6H), docked with or without Amber MD/HSA bridging waters, including results from
the GScore selection script. (A) GScores from Glide SP with the GLL δ-OR antagonist library
against the inactive conformation of the high-resolution δ-OR (PDB ID: 4N6H) with or without
water locations and orientations predicted using Amber MD/HSA; and (B) the top 1% or 2% of
ligands identified using GScore selection script. All successfully docked (RMSD < 2.0 Å) ligands
containing benzomorphan core (red), unsuccessfully docked (RMSD > 2.0 Å) ligands containing
benzomorphan core (black), and ligands of unknown docking success that contain no
benzomorphan core (green).
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The Glide SP run of the δ-OR antagonist library and structurally similar decoys (GLL and
GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID: 4N6H), a whisker
plot was made (Fig 27) for known active ligands to reveal the fate of actives with a benzomorphan
core and known superior ligand pose (red, RMSD < 2.0 Å), benzomorphan core and inferior ligand
pose (black, RMSD > 2.0 Å), and ligands without a benzomorphan core (green). Ligands with
benzomorphan cores were preferentially enriched and ligands without benzomorphan cores
failed to enrich using Glide SP. The post-processing script also failed to enrich ligands without
benzomorphan cores into the top 1% or 2%. However, the δ-OR antagonist library contains only
3 ligands without benzomorphan cores. Different results may be obtained with libraries
containing larger numbers of ligands without benzomorphan cores, through the preference for
enrichment of ligands with benzomorphan cores will be expected, even in that case.

6.6 High-resolution vs. Low-resolution delta-OR: HSA waters
We have seen that Amber MD/HSA can be used to predict the locations and orientations
of bridging water molecules and improve ligand-receptor docking metrics as well as bridging
waters obtained using Maestro. Maestro requires resolved oxygen densities in the x-ray crystal
structure models to predict the locations of waters, and then deduce orientations for placed
water molecules, whereas Amber MD/HSA does not require resolved oxygen densities. However,
these results were achieved using the inactive conformation of the high-resolution δ-OR (PDB ID:
4N6H, 1.80 Å) and the question remains whether Amber MD/HSA can predict the locations and
orientations of bridging waters for low-resolution structures, such as δ-OR (PDB ID: 4EJ4, 3.40 Å),
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and whether the subsequent docking metrics will improve as greatly with the inclusion of waters
generated for a low-resolution receptor.

6.6.1 Enrichment Curves and AUC
Enrichment curves and AUC values for ligand-receptor docking of δ-OR antagonists
against the high-resolution δ-OR (PDB ID: 4N6H, 1.8 Å) using water locations taken from x-ray
crystal structures models and water orientations predicted using Maestro (Fig 28. A, B) or water
locations and orientations predicted using Hydration Site Analysis applied to output from Amber
MD simulations (Fig 28. C, D). Inclusion of bridging waters during ligand-receptor docking
improves AUC values using Glide HTVS (A, C) or Glide SP (B, D) compared to docking without
bridging waters.

80

Figure 28. Inclusion of Amber MD/HSA bridging water molecules during ligand-receptor
docking against the low-resolution δ-OR and the high-resolution δ-OR improves enrichment of
known δ-OR antagonists from a rigorous library of structurally similar decoys (GDD Library)
when compared to docking without waters. The inclusion of Amber MD/HSA bridging waters
during ligand-receptor docking to the inactive conformation of the low-resolution δ-OR (PDB
ID: 4EJ4)(A, B) improves overall enrichment of known δ-OR antagonists from a rigorous library
of structurally similar decoys (GDD Library) as well as docking with the inclusion of bridging
waters generated for the high-resolution δ-OR (PDB ID: 4N6H) (C, D) when curves and AUC
values are compared for the relatively small δ-OR antagonist library.
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The docking results for δ-OR antagonists (GLL) and decoys (GDD) against the lowresolution δ-OR (PDB ID: 4EJ4) were compared to the docking results for the high-resolution δOR (PDB ID: 4N6H). For both structures, water locations and orientations were predicted using
HSA applied to output from Amber MD simulations. Enrichment curves for δ-OR antagonists
docked against the low-resolution δ-OR (Fig 28) reveal, using either Glide HTVS or SP, that
inclusion of bridging waters improved ligand-receptor docking enrichment when compared to
docking without bridging water molecules. Area under the curve (AUC) calculations show modest
improvements when docking with bridging waters is compared to docking without bridging
waters. Increasing AUC values, with the addition of bridging waters, describe overall
improvement to docking enrichment. We should consider that these docking runs were made
with default settings for receptor preparation and ligand-receptor docking, for the most part, and
no attempt was made to use other means to improve docking enrichment, such as requiring
interactions with specific residues or bridging water molecules, or docking to multiple receptor
conformations. In this way, we show only the effect of the addition of bridging waters without
other confounding factors to affect the result.

6.6.2 BedROC and RIE
Moreover, we are most interested in improvements to ligand-receptor docking
enrichment for the top 1-2% of hits. Increasing the α variable in BedROC calculations shifts
emphasis to earlier hits. Using α = 20.0, BedROC is modulated to emphasize the first 8% of the
top-ranked molecules to account for 80% of the score. The ratio of 15 active ligands to total
ligands, including 624 structurally similar decoys, for the δ-OR antagonist library is 0.023 (n/N =
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15/639). Tuning parameters (α) were therefore set to 20.0 and 8.0, and were used to measure
the probability that an active compound would be ranked before a randomly selected compound
(n/N*α << 1 for either value). BedROC values indicate that inclusion of bridging water molecules
during ligand-receptor docking improves early recognition of active compounds in δ-OR
antagonist library (GLL) and decoy library (GDD) docked against the high-resolution and the lowresolution δ-ORs (Fig 29). Similar trends were obtained using α = 8.0 for BedROC calculations.
Robust initial enhancement (RIE) results also revealed increasing RIE values, which supports the
results obtained from BedROC calculations.

Figure 29. Inclusion of Amber MD/HSA waters during ligand-receptor docking of δ-OR
antagonists (GLL library) and GPCR decoy database (GDD) against the inactive conformations
of the high-resolution δ-OR (PDB ID: 4N6H) and the low-resolution δ-OR (PDB ID: 4EJ4)
improves BedROC and robust initial enhancement (RIE) values. Inclusion of waters obtained
using Amber MD/HSA for the low-resolution δ-OR (PDB ID: 4EJ4) performed almost as well
waters obtained for the high-resolution δ-OR (PDB ID: 4N6H).
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6.6.3 Enrichment Factors
Enrichment factors increased with the inclusion of Amber MD/HSA bridging waters for
the top 1, 2, 5, and 10% of the screened δ-OR antagonist library for the low-resolution δ-OR (PDB
ID: 4EJ4) almost as well as with the high-resolution δ-OR (PDB ID: 4N6H) using Glide HTVS or SP
(Fig 30). The effect of the inclusion of water molecules was most obvious for the top 1% or 2% of
screened ligands, particularly with the inclusion of several bridging waters.

Figure 30. Inclusion of Amber MD/HSA bridging water molecules during ligand-receptor
docking of known δ-OR antagonists (GLL) to the low-resolution δ-OR (PDB ID: 4EJ4) improves
enrichment factors. Enrichment factors improved with the inclusion of bridging waters
(obtained using Amber MD/HSA) for docking of the δ-OR antagonist (GLL library) and
structurally similar decoys (GDD library) to the low-resolution δ-OR (PDB ID: 4EJ4) almost as
well as docking with bridging waters obtained using Amber MD/HSA against the highresolution δ-OR (PDB ID: 4N6H), using Glide HTVS or Glide SP. The most significant increases to
enrichment factors were obtained for the top 1 or 2% of screened ligands.
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6.6.4 Relative GScores
For the low-resolution δ-OR (PDB ID: 4EJ4), most known active δ-OR antagonists (GLL
library) enjoyed decreasing GScores (Fig 31) with the inclusion of bridging waters and most
structurally similar decoys (GDD library) suffered increasing GScores with the inclusion of bridging
waters as revealed in GScore plots for ligand-receptor docking using Glide HTVS (C) or Glide SP
(D). These results can be compared to those from ligand-receptor docking to the high-resolution
δ-OR (PDB ID: 4N6H) using Glide HTVS (A) or SP (B). For all GScore plots (A-D), red coordinates
represent known active ligands and black coordinates represent structurally similar decoys.
GScore plots are shown for water locations and orientations obtained using Amber MD/HSA
waters. As for the high-resolution δ-OR (PDB ID: 4N6H), docking to the low-resolution δ-OR (PDB
ID: 4EJ4) in the presence of Amber MD/HSA bridging waters produced improvements to docked
ligand rankings of active compounds, with the inclusion of bridging waters during docking, as a
consequence of decreasing GScores for known active δ-OR antagonists and increasing GScores
for structurally similar decoys (Fig 31).
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Figure 31. Relative GScores from docking ‘without bridging waters’ versus docking ‘with 3
bridging waters’ of known δ-OR antagonists (GLL) and decoys (GDD) against the low-resolution
δ-OR (PDB ID: 4EJ4) and the high-resolution δ-OR (PDB ID: 4N6H) using Glide HTVS or Glide SP.
Relative GScores from (Glide HTVS or SP) docking of known δ-OR antagonists (GLL) and decoys
(GDD) to the low-resolution δ-OR (PDB ID: 4EJ4) and the high-resolution δ-OR (PDB ID: 4N6H),
in each case, ‘without bridging waters’ versus docking ‘with 3 bridging waters’. GScore plots
for ligand-receptor docking using Glide HTVS (A, C) or Glide SP (B, D) and the δ-OR antagonist
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library (GLL) with structurally similar decoys (GDD). For all GScore plots (A-D), red coordinates
represent known active ligands and black coordinates represent structurally similar decoys. For
all relative GScore plots (A-D), water locations and orientations were obtained using Amber
MD/HSA waters.

6.6.5 Ligand Sorting Script and “Equivalent Enrichment Factor”
Unlike results from the δ-OR antagonist library docked to the inactive conformation of
the high-resolution δ-OR (PDB ID: 4N6H) using Glide HTVS (B) or Glide SP (D), the sorting script
gave poor results (Fig 32) for the δ-OR antagonist library docked to the inactive conformations of
the low-resolution δ-OR (PDB ID: 4EJ4) using results from either Glide HTVS (C) or SP (E).

87

Figure 32. Inclusion of HSA-obtained bridging waters during ligand-receptor docking of known
δ-OR antagonists (GLL library) and structurally similar decoys (GDD Library) to the inactive lowresolution δ-OR (PDB ID: 4EJ4) and the high-resolution δ-OR (PDB ID: 4N6H) improves
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enrichment factors. The sorting process for the “equivalent enrichment factor” failed to
produce improvements. (A) Enrichment factors for the top 1, 2, 5, and 10% of docked (HTVS
and SP) δ-OR antagonists (GLL) and decoys (GDD) for the low-resolution δ-OR (PDB ID: 4EJ4)
and the high-resolution δ-OR (PDB ID: 4N6H). A sorting script (B-E) failed to improve
“equivalent enrichment” or even retain active ligands for the low-resolution δ-OR (C, E) during
the sorting process as well as it did for docking results obtained using the high-resolution δ-OR
(B,D). The sorting process worked poorly for the low-resolution δ-OR using results from either
Glide HTVS (C) or SP (E), unlike results from the high-resolution δ-OR using results from either
Glide HTVS (B) or SP (D), despite the improvements to the enrichment factors obtained from
ligand-receptor docking in the presence of bridging waters.

6.7 High-resolution Inactive delta-OR vs. delta-OR Agonist Library
We have seen that Amber MD/HSA can be used to predict the locations and orientations
of bridging waters for inactive conformations of the high-resolution δ-OR (PDB ID: 4N6H, 1.80 Å)
and low-resolution δ-OR (PDB ID: 4EJ4, 3.40 Å), and that use of these waters can improve ligandreceptor docking metrics. We now ask whether known δ-OR agonists might be enriched with the
inclusion of bridging waters when docking to inactive conformations of the δ-OR and, if so,
whether these actives will contain only the benzomorphan core found in the co-crystallized
ligand or other ligand cores might be enriched using this method.
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6.7.1 Enrichment Curves and AUC
Glide HTVS docking results for the δ-OR agonist library against the low-resolution (A) or
high-resolution δ-OR (B) using Glide HTVS (Fig 33) were poor overall. The Glide SP docking result
for the low-resolution δ-OR (C) was poor overall, but the high-resolution δ-OR (D) offered
reasonable improvements to the enrichment curve and AUC values when compared to docking
without bridging waters.
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Figure 33. Inclusion of Amber MD/HSA bridging water molecules during ligand-receptor
docking against the inactive low-resolution δ-OR and the inactive high-resolution δ-OR
improves enrichment of known δ-OR agonists from a rigorous library of structurally similar
decoys (GDD Library) when compared to docking without waters. Docking of δ-OR agonist
libraries (GLL) and structurally similar decoys (GDD) to inactive conformations of high- and lowresolution δ-ORs (PDB IDs: 4N6H and 4EJ4, respectively) in the presence of Amber MD/HSA
bridging waters slightly improved overall enrichment of known actives (A-C) and there was
some reasonable improvement for the Glide SP docking run against the high-resolution δ-OR
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(D). However, early recognition improved for the low-resolution δ-OR (A, C) and highresolution δ-OR (B, D) for the δ-OR agonist library using either Glide HTVS (A, B) or Glide SP (C,
D).

6.7.2 BedROC and RIE
Ligand-receptor docking of the δ-OR agonist library to the inactive conformations of the
high-resolution δ-OR (PDB ID: 4N6H) and the low-resolution δ-OR (PDB ID: 4EJ4) revealed
improvements to early enrichment as measured by BedROC and RIE values (Fig 34). We are most
interested in early recognition of active ligands.

Figure 34. Inclusion of HSA-obtained bridging waters during ligand-receptor docking of δ-OR
agonists (GLL library) and GPCR decoy database (GDD) ligands against the low-resolution δ-OR
(PDB ID: 4EJ4) and high-resolution δ-OR (PDB ID: 4N6H) improves BedROC and robust initial
enhancement (RIE) values. Early enrichment for the docking of the δ-OR agonist library to the
high- and low-resolution δ-OR (PDB IDs: 4N6H and 4EJ4, respectively) improved with the
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inclusion of waters. BedROC and RIE values increased with the inclusion of bridging water
molecules.

6.7.3 Enrichment Factors
Enrichment factors increased for the top 1% and 2% of the δ-OR agonist library, using
Glide HTVS or SP, with the inclusion of Amber MD/HSA waters with the inactive conformations
of the high-resolution δ-OR (PDB ID: 4N6H) and the low-resolution δ-OR (PDB ID: 4EJ4) (Fig 35).
The effect of the inclusion of water molecules was most obvious for the top 1% or 2% of screened
ligands, particularly with the inclusion of several bridging waters, though very marginal
improvements were seen at 5% and 10% for the Glide SP runs against the high-resolution δ-OR
(PDB ID: 4N6H).

Figure 35. Early enrichment factors improve with the inclusion of Amber MD/HSA bridging
waters during ligand-receptor docking of known δ-OR agonists to the high- and low-resolution
δ-OR (PDB IDs: 4N6H and 4EJ4). Early enrichment factors at 1% and 2% improved with the
inclusion of Amber MD/HSA bridging waters for ligand-receptor docking of the δ-OR agonist
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(GLL library) and structurally similar decoys (GDD library) to the high-resolution δ-OR (PDB ID:
4N6H) and low-resolution δ-OR (PDB ID: 4EJ4) using Glide HTVS or Glide SP.

6.7.4 Ligand Sorting Script and “Equivalent Enrichment Factor”
The sorting process worked poorly for output from the δ-OR agonist library (Fig 36)
against the inactive conformations of the low-resolution δ-OR using results from either Glide
HTVS (B) or SP (D), and from Glide HTVS (C) from docking runs against the high-resolution δ-OR
(PDB ID: 4N6H). This result might have been expected with the marginal improvements to the
enrichment factors obtained from ligand-receptor docking in the presence of bridging waters,
however, using data from Glide SP obtained with the active library against the inactive
conformation of the high-resolution δ-OR (PDB ID: 4N6H), the sorting script appeared to improve
our ability to identify active ligands (E).
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Figure 36. Inclusion of HSA-obtained bridging waters during ligand-receptor docking of known
δ-OR agonists (GLL library) and structurally similar decoys (GDD Library) to the inactive low-
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resolution δ-OR (PDB ID: 4EJ4) and the high-resolution δ-OR (PDB ID: 4N6H) improves
enrichment factors. The sorting process for the “equivalent enrichment factor” failed to
produce improvements except for results obtained from docking to the high-resolution δ-OR
using Glide SP. (A) Enrichment factors for the top 1, 2, 5, and 10% of docked (HTVS and SP) δOR agonists (GLL) and decoys (GDD) for the low-resolution δ-OR (PDB ID: 4EJ4) and the highresolution δ-OR (PDB ID: 4N6H). A sorting script (B-E) failed to improve “equivalent
enrichment” for the low-resolution δ-OR (B, D) or the Glide HTVS output (C) for the highresolution δ-OR as well as it did for docking results obtained using Glide SP against the highresolution δ-OR (E).

6.7.5 Ligand Cores and GScores
For the Glide HTVS run of the δ-OR agonist library and structurally similar decoy database
library (GLL and GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID:
4N6H), a whisker plot was made (Fig 37) for ligands docked with or without Amber MD/HSA
bridging waters showing the resulting GScores for known actives with a benzomorphan core and
with a known reasonable ligand pose (red, RMSD < 2.0 Å), known actives with a benzomorphan
core and inferior ligand pose (black, RMSD > 2.0 Å), and known active ligands without a
benzomorphan core (green). Ligands with benzomorphan cores were preferentially enriched, for
the most part, which is expected since the co-crystallized ligand contains a benzomorphan core.
However, some ligands without benzomorphan cores did enjoy improved GScores for the Glide
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HTVS docking run. Moreover, the post-processing script identified known ligands without
benzomorphan cores in the top 1% (9/27) and 2% (11/37).

Figure 37. Whisker plot of GScores from docking results using Glide HTVS with δ-OR agonist
libraries (GLL) and decoys (GDD) against the inactive conformation of the high-resolution δ-OR
(PDB ID: 4N6H), docked with or without Amber MD/HSA bridging waters, including results from
the GScore selection script. Docking results using Glide HTVS with δ-OR agonist libraries (GLL)
and decoys (GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID:
4N6H), docked with or without water locations and orientations predicted using bridging
waters obtained from Amber MD/HSA for docking to obtain GScores for (A) successfullydocked ligands (RMSD < 2.0 Å, red) containing a benzomorphan core, unsuccessfully-docked
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ligands (RMSD > 2.0 Å, black) containing a benzomorphan core, and ligands containing no
benzomorphan core (green), and (B) the top 1% or 2% of ligands identified using the GScore
selection script.

The Glide SP run of the δ-OR agonist library and structurally-similar decoy database library
(GLL and GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID: 4N6H)
produced a whisker plot (Fig 38) for ligands docked with or without Amber MD/HSA bridging
waters showing the resulting GScores for known actives with a benzomorphan core and known
reasonable ligand pose (red, RMSD < 2.0 Å), known actives with a benzomorphan core and known
inferior ligand pose (black, RMSD > 2.0 Å), and known active ligands without a benzomorphan
core (green) with an unknown quality of pose. Ligands with benzomorphan cores were
preferentially enriched, in general, because the co-crystallized ligand contains a benzomorphan
core. However, some ligands without benzomorphan cores enjoyed improved GScores for the
Glide SP docking run. Moreover, the post-processing script identified many known ligands
without benzomorphan cores in the top 1% (29/60) and 2% (32/63), most of which were found
in the top 1%.
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Figure 38. Whisker plot of GScores from docking results using Glide SP with δ-OR agonist
libraries (GLL) and decoys (GDD) against the inactive conformation of the high-resolution δ-OR
(PDB ID: 4N6H), docked with or without Amber MD/HSA bridging waters, including results from
the GScore selection script. Docking results using Glide SP with δ-OR agonist libraries (GLL)
and decoys (GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID:
4N6H), docked with or without water locations and orientations predicted using bridging
waters obtained from Amber MD/HSA for docking to obtain GScores for (A) successfullydocked ligands (RMSD < 2.0 Å, red) containing a benzomorphan core, unsuccessfully-docked
ligands (RMSD > 2.0 Å, black) containing a benzomorphan core, and ligands containing no
benzomorphan core (green), and (B) the top 1% or 2% of ligands identified using the GScore
selection script.
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6.8 High-resolution Inactive delta-OR vs. mu-OR Agonist Library
We have seen that Amber MD/HSA can be used to predict the locations and orientations
of bridging waters for inactive conformations of the high-resolution δ-OR (PDB ID: 4N6H, 1.80 Å)
and low-resolution δ-OR (PDB ID: 4EJ4, 3.40 Å), and that use of these waters can improve ligandreceptor docking metrics. We have also seen that known δ-OR agonists might enjoy some early
enrichment with the inclusion of bridging waters when docking to inactive conformations of the
δ-OR and these actives contain both the benzomorphan core found in the co-crystallized ligand,
as expected, and a relatively large number of other ligand cores. Now we want to know whether
we will enrich many known µ-OR agonists from the GLL library while recognizing that δ-OR and
µ-OR do share many ligands. However, there are differences in the libraries, and we did obtain
different results.
6.8.1 Enrichment Curves and AUC
Ligand-receptor docking results were similar for the µ-OR agonist library against the lowor high-resolution δ-OR using Glide HTVS (Fig 39 A, B). AUC values reveal little or no overall
improvement to docking enrichment for the δ-OR agonist library using Glide HTVS, but
reasonable overall improvements to docking enrichment were obtained using Glide SP (Fig 39 C,
D). However, early recognition improved for the low-resolution δ-OR (A, C) and high-resolution
δ-OR (B, D) for the δ-OR agonist library using either Glide HTVS (A, B) or Glide SP (C, D).
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Figure 39. Inclusion of Amber MD/HSA bridging water molecules during ligand-receptor
docking against the inactive low-resolution δ-OR and the inactive high-resolution δ-OR
improves enrichment of known µ-OR agonists from a rigorous library of structurally similar
decoys (GDD Library) when compared to docking without waters. Docking of µ-OR agonist
libraries (GLL) and structurally similar decoys (GDD) to inactive conformations of the highresolution δ-OR (B, D) and low-resolution δ-OR (A, C) in the presence of bridging waters (Amber
MD/HSA) slightly improved overall enrichment of known active for Glide HTVS docking runs (A,
B) and produced reasonably good improvements for Glide SP docking runs (C, D).
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6.8.2 BedROC and RIE
Ligand-receptor docking of the µ-OR agonist library to the inactive conformations of the
high-resolution δ-OR (PDB ID: 4N6H) and the low-resolution δ-OR (PDB ID: 4EJ4) revealed
improvements to early enrichment as measured by BedROC and RIE values (Fig 40). We are most
interested in early recognition of active ligands, particularly µ-OR agonists because activation of
the µ-OR is primarily responsible for the analgesic effects of opioids.

Figure 40. Inclusion of HSA-obtained bridging waters during ligand-receptor docking of µ-OR
agonists (GLL library) and GPCR decoy database (GDD) ligands against the low-resolution δ-OR
(PDB ID: 4EJ4) and high-resolution δ-OR (PDB ID: 4N6H) improves BedROC and robust initial
enhancement (RIE) values. BedROC and RIE values increased, with the addition of Amber
MD/HSA bridging water molecules, indicating that early enrichment for the docking of the µOR agonist library to inactive conformations of the high- and low-resolution δ-OR (PDB IDs:
4N6H and 4EJ4, respectively), using Glide HTVS or SP, improved with the inclusion of waters.
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6.8.3 Enrichment Factors
Early enrichment factors at 1% and 2% increased with the inclusion of waters for ligandreceptor docking of the µ-OR agonist (GLL library) and structurally similar decoys (GDD library) to
the inactive conformations of the high-resolution δ-OR (PDB ID: 4N6H) and low-resolution δ-OR
(PDB ID: 4EJ4), using Glide HTVS or Glide SP, with the inclusion of Amber MD/HSA waters (Fig 41).
The effect of the inclusion of water molecules was most obvious for the top 1% or 2% of screened
ligands, particularly with the inclusion of several bridging waters, though very marginal
improvements, if any, were seen at 5% and 10% for the Glide SP runs against the high-resolution
δ-OR (PDB ID: 4N6H).

Fig 41. Early enrichment factors improve with the inclusion of Amber MD/HSA bridging waters
during ligand-receptor docking of known µ-OR agonists to the high- and low-resolution δ-OR
(PDB IDs: 4N6H and 4EJ4). Early enrichment factors for known µ-OR agonists docked against
the low-resolution inactive conformation of the δ-OR (PDB IDs: 4EJ4) somewhat improved (for
the top 1% and 2%) with the inclusion of Amber MD/HSA bridging waters. Early enrichment
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factors for known µ-OR agonists docked against the high-resolution inactive conformation of
the δ-OR (PDB IDs: 4N6H) showed reasonable improvement (for the top 1% and 2%) with the
inclusion of bridging waters.

6.8.4 Ligand Sorting Script and “Equivalent Enrichment Factor”
The sorting process (Fig 42) worked well for output from the µ-OR agonist library docking
to the inactive conformations of the low-resolution (D) and high-resolution (E) δ-OR using Glide
SP (D, E), but not for the inactive conformations of the low-resolution (B) and high-resolution (C)
δ-OR using Glide HTVS (B, C). This result somewhat reflects the marginal improvements to the
enrichment factors obtained from ligand-receptor docking in the presence of bridging waters,
but the result is inconsistent. Using Glide HTVS against the high-resolution δ-OR, we obtained
improvements to enrichment factors (A) with the inclusion of Amber MD/HSA bridging waters
but the sorting script failed to improve the “equivalent enrichment.” On the other hand, using
Glide SP, the sorting script only somewhat improved “equivalent enrichment” for the lowresolution δ-OR (D) but it very much improved the “equivalent enrichment” for the highresolution δ-OR (E).
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Figure 42. Inclusion of HSA-obtained bridging waters during ligand-receptor docking of known
µ-OR agonists (GLL library) and structurally similar decoys (GDD Library) to the inactive low-
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resolution δ-OR (PDB ID: 4EJ4) and the high-resolution δ-OR (PDB ID: 4N6H) improves
enrichment factors. The sorting process for the “equivalent enrichment factor” improved
results from docking using Glide SP. (A) Enrichment factors for the top 1, 2, 5, and 10% of
docked (HTVS and SP) µ-OR agonists (GLL) and decoys (GDD) for the low-resolution δ-OR (PDB
ID: 4EJ4) and the high-resolution δ-OR (PDB ID: 4N6H). A sorting script (B-E) failed to improve
“equivalent enrichment” for the low-resolution and high-resolution δ-OR Glide HTVS output
(B, C). However, the sorting script somewhat improved the “equivalent enrichment” for the
low-resolution δ-OR Glide SP output (D) and greatly improved the “equivalent enrichment” for
the top 1% for the high-resolution δ-OR Glide SP output (E).

6.8.5 Ligand Cores and GScores
The µ-OR agonist and structurally similar decoy database libraries (GLL and GDD) were
run using Glide HTVS against the inactive conformation of the high-resolution δ-OR (PDB ID:
4N6H). The results were used to produce a whicker plot (Fig 43). Known active ligands docked in
the presence of bridging waters (Amber MD/HSA) show, when compared to docking without
waters, decreases in the resulting GScores for known actives with a benzomorphan core and a
known reasonable ligand pose (red, RMSD < 2.0 Å) and for a few known active ligands without a
benzomorphan core (green). However, many known actives with a benzomorphan core and
inferior ligand pose (black, RMSD > 2.0 Å) did not enjoy improved enrichment, and four ligands
that previously had docked with a reasonable pose were lost with the inclusion of bridging
waters.
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Figure 43. Whisker plot of GScores from docking results using Glide HTVS with µ-OR agonist
libraries (GLL) and decoys (GDD) against the inactive conformation of the high-resolution δ-OR
(PDB ID: 4N6H), docked with or without Amber MD/HSA bridging waters. GScores obtained
from docking using Glide HTVS (A), with or without inclusion of Amber MD/HSA bridging
waters, for the µ-OR agonist library (GLL) and structurally similar decoys (GDD) docked against
the inactive conformation of the high-resolution δ-OR (PDB ID: 4N6H). Known active ligands
were divided into three groups: successfully docked ligands (RMSD < 2.0 Å, red) containing a
benzomorphan core, unsuccessfully docked ligands (RMSD > 2.0 Å, black) containing a
benzomorphan core, and ligands containing no benzomorphan core (green).
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Fig 44. Whisker plot of GScores from docking results using Glide SP with µ-OR agonist libraries
(GLL) and decoys (GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID:
4N6H), docked with or without Amber MD/HSA bridging waters, including results from the
GScore selection script. Docking results using Glide SP with µ-OR agonist libraries (GLL) and
decoys (GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID: 4N6H),
docked with or without water locations and orientations predicted using bridging waters
obtained from Amber MD/HSA for docking to obtain GScores for (A) successfully-docked
ligands (RMSD < 2.0 Å, red) containing a benzomorphan core, unsuccessfully-docked ligands
(RMSD > 2.0 Å, black) containing a benzomorphan core, and ligands containing no
benzomorphan core (green), and (B) the top 1% or 2% of ligands identified using the GScore
selection script.
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The Glide SP run of the µ-OR agonist library and structurally similar decoy database library
(GLL and GDD) against the inactive conformation of the high-resolution δ-OR (PDB ID: 4N6H)
produced a whisker plot (Fig. 44) for ligands docked with or without Amber MD/HSA bridging
waters showing the resulting GScores for known actives with a benzomorphan core and known
reasonable ligand pose (red, RMSD < 2.0 Å), known actives with a benzomorphan core and known
inferior ligand pose (black, RMSD > 2.0 Å), and known active ligands without a benzomorphan
core (green) with an unknown quality of pose. Ligands with benzomorphan cores were
preferentially enriched, in general, because the co-crystallized ligand contains a benzomorphan
core. However, a few ligands without benzomorphan cores enjoyed decreased GScores for the
Glide SP docking run. The post-processing script identified mostly known ligands with
benzomorphan cores in the top 1% (25/30) and 2% (25/30), all of which were found in the top
1%.
Opioid Results Summary
Amber MD/HSA successfully predicted useful locations and orientations of bridging
waters for high- and low-resolution δ-OR x-ray crystal structure models. The relative accuracy of
the predicted bridging water locations is supported by the presence of oxygen densities of
purported bridging waters in the higher-resolution x-ray crystal structure models of the classical
opioid receptors (δ-OR, µ-OR, κ-OR). Moreover, classical opioid receptor models (PDB IDs: 4N6H,
4DKL, 5C1M, and 4DJH) for higher-resolution structures that contained oxygen densities of
purported bridging waters were prepared using Maestro to predict the orientations of the
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bridging water molecules based on the locations of the oxygen densities. The prepared x-ray
crystal structure models and Maestro bridging waters were validated using docked ligand poses
compared to ligand poses found in x-ray crustal structure models (RMSD < 1.00 Å) and docking
with or without bridging water molecules. Docking in the presence of bridging waters led to
decreased GScores. These bridging waters were used for ligand-receptor docking and produced
improvements to ligand-receptor docking results that established the usefulness of including
these bridging waters for ligand-receptor docking enrichment and they established a reasonable
baseline to compare the results obtained using bridging waters whose locations and orientations
were predicted using Amber MD/HSA.

Docking of δ-OR, µ-OR, and κ-OR antagonists to inactive δ-OR, µ-OR, and κ-OR, respectively, using
Maestro bridging waters
We found that several prepared x-ray crystal structure models of inactive classical opioid
receptors (δ-OR, µ-OR, and κ-OR) can be used with oxygen densities (found in the PDB file) and
Maestro-predicted probable orientations of purported bridging water molecules to improve
overall enrichment, early recognition, and early enrichment of known antagonists, using Glide
HTVS or Glide SP. Ligand-receptor docking of known δ-OR, µ-OR, and κ-OR antagonists to higherresolution δ-OR, µ-OR, and κ-OR inactive structures, respectively, (PDB IDs: 4N6H, 4DKL, 4DJH)
with the inclusion of Maestro bridging water molecules, improved overall enrichment as
measured by AUC values, early recognition as measured by BedROC and RIE values, and early
enrichment as measured by enrichment factors at 1%, 2%, 5%, and 10%. Overall enrichment
improved, as measured by the AUC, in all cases when docking with the inclusion of Maestro
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bridging waters, when compared to docking without bridging waters using either Glide HTVS or
Glide SP (Figs 10, 16). In general, Glide HTVS tended to perform as well or somewhat better
overall, in terms of AUC values, with the inclusion of Maestro bridging waters. Early recognition,
in terms of BedROC (α = 8.0, α = 20.0) or RIE, also improved using either Glide HTVS or SP (Figs
11, 17). BedROC and RIE results using Glide HTVS or SP were comparable for - (PDB ID: 4N6H) but
Glide HTVS performed better for µ-OR and κ-OR (PDB IDs: 4DKL and 4DJH). Early enrichment
factors improved (1%, 2%, 5%, and 10%) with the inclusion of Maestro bridging waters (Figs 12,
18) for µ-OR, κ-OR, and δ-OR but, again, Glide HTVS performed better. In all cases, the most
significant results were obtained for enrichment to the top 1 and 2%, particularly the top 1%.
The post-processing script used a ΣΔGScores cutoff (kJ/mol) below which ligands were
removed (Figs 12 and 25). The remaining ligands were treated as the top 1% or 2%. Using Glide
HTVS against the µ-OR and κ-OR, the best results were obtained using cutoffs between 0.70 and
1.05 kJ/mol for the top 2% and using cutoffs between 0.85 and 1.45 kJ/mol for the top 1%. Using
Glide SP, the best results were obtained using cutoffs between 0.70 and 0.75 kJ/mol for the top
2% and using cutoffs between 0.95 and 1.10 kJ/mol for the top 1%. The resulting so-called
"equivalent enrichment factors" generally failed to improve the enrichment factors obtained only
from docking, but the equivalent enrichment factor was significantly better for the κ-OR using
Glide SP and the equivalent enrichment factor was worse for µ-OR using Glide HTVS.
Improvements to ligand-receptor docking enrichment of known active ligands with the inclusion
of bridging water molecules can be attributed to decreasing GScores for docked known actives
but less often for docked decoys. More specifically, decreasing GScores correlated with more
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favorable hydrogen bond formation and electrostatic interactions with known actives in the
presence of bridging waters (Fig 23) when docking using Glide XP.

Docking of µ-OR agonists to active µ-OR using Maestro bridging waters
We found that the prepared x-ray crystal structure model of the active µ-OR can be used
with oxygen densities (found in the PDB file) and Maestro-predicted probable orientations of
purported bridging waters generally failed to improve overall enrichment, early recognition, and
early enrichment of known agonists, using Glide HTVS or Glide SP. Results could be improved
with the removal of the N-terminus, but even then, results were not particularly good. The best
results were obtained using the post-processing script on the output from docking using Glide SP.
This difficulty is highly relevant as the active µ-OR is the primary mediator of analgesia. If we want
to find new painkillers, we are generally looking for µ-OR agonists. Docking to the active structure
of µ-OR (PDB ID: 5C1M) presents a difficult case. The N-terminus of the µ-OR extends into the
orthosteric binding pocket where the H54 side chain forms a hydrogen bond with the bound
agonist BU72. The N-terminus also partially obstructs the binding pocket. Ligand-receptor
docking of known µ-OR agonists to the active high-resolution µ-OR (PDB ID: 5C1M) including the
N-terminus, with the inclusion of Maestro bridging water molecules, somewhat improved overall
enrichment as measured by AUC values (Fig 13). Improvements to early recognition, as measured
by BedROC and RIE values, were of small significance (Fig 14). Enrichment factors failed to
improve beyond the addition of one bridging water (Fig 15). That improvement was insignificant.
Removal of the N-terminus followed by ligand-receptor docking somewhat improved overall
enrichment measured by AUC values, but early enrichment factors and early recognition
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(BedROC and RIE) values declined, except with the addition of all three waters (Figs 13-15). The
post-processing script improved the equivalent enrichment factor at 1% and 2% only in the
absence of the N-terminus (Fig 15). Using Glide SP, the best results were obtained using a 0.65
kJ/mol cutoff for the top 2% and using a 1.05 kJ/mol cutoff for the top 1%.

Docking of δ-OR antagonists to high-res inactive δ-OR using Amber MD/HSA bridging waters
We found that the x-ray crystal structure model of the inactive high-resolution δ-OR can
be used with probable locations and orientations of purported bridging waters (obtained using
Amber MD/HSA) to improve overall enrichment, early recognition, and early enrichment of
known antagonists, using Glide HTVS or Glide SP. Ligand-receptor docking of δ-OR antagonists to
the high-resolution δ-OR (PDB ID: 4N6H) using Amber MD/HSA bridging waters performed about
as well, in most cases, as waters obtained using oxygen densities in Maestro despite that Amber
MD/HSA had to predict the locations of water molecules while Maestro enjoyed the advantage
of using oxygen densities to locate water molecules. Ligand-receptor docking with the inclusion
of Amber MD/HSA bridging waters improved overall enrichment (AUC), early recognition
(BedROC and RIE), and early enrichment (EF), when compared to ligand-receptor docking without
waters. As before, Glide HTVS outperformed Glide SP for overall enrichment (Fig 16). Bridging
waters obtained using Maestro performed better than bridging waters obtained using Amber
MD/HSA, marginally so when using Glide HTVS and more so when using Glide SP, in terms of
overall enrichment (AUC). However, we are more concerned with early enrichment and early
recognition. Ligand-receptor docking results were comparable between Amber MD/HSA and
Maestro waters for early recognition (Fig 17), in terms of BedROC (α = 8.0, α = 20.0) or RIE. Early
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enrichment measures (EF) were also comparable (Fig 18), though Maestro waters performed
better using HTVS and Amber MD/HSA waters tended to perform better using Glide SP to obtain
enrichment factors at 1% or 2%. The improvements to ligand-receptor docking enrichment using
either water model can be attributed to a reduction in GScore with the inclusion of water
molecules (Fig 19). Glide SP produced the most consistent ΔGScores with the inclusion of bridging
waters as compared to docking without bridging water molecules. Glide HTVS produced a greater
range of ΔGScores (kJ/mol) with the inclusion of bridging waters. Using Amber MD/HSA waters,
decreasing GScores (kJ/mol) again correlated with more favorable hydrogen bond formation and
electrostatic interactions with known actives in the presence of bridging waters (Fig 24) when
docking using Glide XP. Recall that the post-processing script used a ΣΔGScores cutoff (kJ/mol)
below which ligands were removed (Fig 25). The remaining ligands were treated as the top 1% or
2%. Using Glide HTVS against the low- and high-resolution δ-ORs, the best results were obtained
using cutoffs between 0.90 and 0.95 kJ/mol for the top 2% and using cutoffs between 1.20 and
1.35 kJ/mol for the top 1%. Using Glide SP, the best results were obtained using cutoffs between
0.65 and 0.90 kJ/mol for the top 2% and using cutoffs between 0.95 and 1.25 kJ/mol for the top
1%. The resulting so-called "equivalent enrichment factors" failed to improve on the enrichment
factors obtained only from docking (Fig 25). Using Glide HTVS, most ligands with benzomorphan
cores (7/12) the docked with reasonable poses (RMSD < 2.00 Å) without bridging waters (Fig 26).
In the presence of Amber MD/HSA bridging waters, (8/12) ligands with benzomorphan cores
enjoyed reasonable ligand poses and decreased GScores. Ligands without benzomorphan cores
(3/15) did not enjoy decreasing GScores. Using Glide SP, more ligands with benzomorphan cores
(9/12) docked with reasonable poses (Fig 27). In the presence of Amber MD/HSA bridging waters,
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fewer ligands enjoyed reasonable poses (8/15) but those ligands had lower GScores. Again,
ligands without benzomorphan cores (3/15) did not enjoy reasonable ligands poses or
improvements to GScores with or without the inclusion of Amber MD/HSA bridging waters. Using
Glide HTVS followed by the selection script to remove ligands that docked below the ΣΔGScore
cutoff (kJ/mol), 3/15 ligands remained in the top 1% and 5/15 ligands remained in the top 2%
(Fig 26). Using Glide SP followed by the selection script to remove ligands below the ΣΔGScore
cutoff (kJ/mol), 5/15 ligands remained in the top 1% and 7/15 ligands remained in the top 2%
(Fig 27). All remaining known active ligands contained a benzomorphan core whether we used
Glide HTVS or Glide SP.

Docking of δ-OR antagonists to low-res inactive δ-OR using Amber MD/HSA bridging waters
We found that the x-ray crystal structure model of the inactive low-resolution δ-OR can
be used with probable locations and orientations of purported bridging waters (obtained using
Amber MD/HSA) to improve overall enrichment, early recognition, and early enrichment of
known antagonists, using Glide HTVS or Glide SP. The resolution was too low to identify oxygen
densities of purported bridging waters, so results cannot be obtained using Maestro. Ligandreceptor docking of δ-OR antagonists to the low-resolution δ-OR (PDB ID: 4EJ4) was compared to
results from docking to the high-resolution δ-OR (PDB ID: 4N6H) using Amber MD/HSA bridging
waters. The high-resolution δ-OR produced better overall enrichment, as measured by AUC
values, using Glide HTVS and the low-resolution δ-OR produced better overall enrichment using
Glide SP. However, when compared to docking without bridging waters, the inclusion of bridging
water molecules improved overall enrichment in every case (Fig 28). Early recognition (BedROC
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or RIE) improved with the inclusion of Amber MD/HSA bridging waters in every case for both the
high- and low-resolution δ-ORs with the addition of bridging waters (Fig 29). Early enrichment
(EF at 1, 2, 5, and 10%) improved for both low- and high-resolution δ-ORs when compared to
docking without waters, though Glide SP performed somewhat better against high-resolution δOR receptor and Glide HTVS performed somewhat better against the low-resolution δ-OR (Fig
30), particularly at 1% and 2%. For both the low- and high-resolution δ-OR, improvements to the
enrichment of known active ligands can be attributed to lower GScores for most active ligands
and higher GScores for most decoys, when docking in the presence of bridging waters as
compared to docking without waters (Fig 31).
The post-processing script was used across a range of ΣΔGScore cutoffs (kJ/mol). The
remaining ligands were treated as the top 1% or 2%. Using Glide HTVS against the low- and highresolution δ-ORs, the best results were obtained using cutoffs between 0.90 and 0.95 kJ/mol for
the top 2% and using 1.35 kJ/mol for the top 1%. Using Glide SP, the best results were obtained
using cutoffs between 0.90 and 1.10 kJ/mol for the top 2% and using 1.25 kJ/mol for the top 1%.
The resulting so-called "equivalent enrichment factors" performed much worse than the
enrichment factors obtained only from docking (Fig 32).

Why use the inactive δ-OR to enrich δ-OR or µ-OR agonists?
Given the difficulties in the docking of known µ-OR agonists to the active µ-OR (PDB ID:
5C1M), without the removal of the N-terminus, and the diminished usefulness of the inclusion of
bridging waters in the absence of the N-terminus while docking to active µ-OR, we experimented
with the effects of including purported bridging water molecules during the docking of known
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agonists to inactive opioid receptor structure models. The orthosteric binding pockets of δ-OR
and µ-OR are structurally similar, and these receptors share a significant number of ligands. First,
we docked known δ-OR agonists to the inactive δ-OR. Second, we docked known µ-OR agonists
to the inactive δ-OR. In this way, we could separately observe the effects of the activity mismatch
(known δ-OR agonists versus the inactive δ-OR) and the ‘activity + subtype’ mismatch (known µOR agonists versus the inactive δ-OR). Note that the post-processing script, as measured using
the ‘equivalent enrichment factor’, was most useful to improve early enrichment for the docking
of known µ-OR agonists to the active µ-OR without the N-terminus (Fig 15), early enrichment for
the docking of known δ-OR agonists to the inactive δ-OR (Fig 35), and the early enrichment of
known µ-OR actives for the inactive δ-OR (Fig 42).

Docking of δ-OR agonists to inactive δ-ORs using Amber MD/HSA bridging waters
We found that the x-ray crystal structure model of the inactive high-resolution δ-OR can
be used with probable locations and orientations of purported bridging waters (obtained using
Amber MD/HSA) to only somewhat improve overall enrichment, early recognition, and early
enrichment of known δ-OR agonists, using Glide HTVS or Glide SP. The post-processing script for
further improvements worked well using Glide SP against the high-resolution δ-OR. Ligandreceptor docking of δ-OR agonists to the low-resolution δ-OR (PDB ID: 4EJ4) and the highresolution δ-OR (PDB ID: 4N6H) using Amber MD/HSA bridging waters produced some
improvement to overall enrichment when compared to docking without waters. Results were
superior for the high-resolution δ-OR, as measured by AUC values, using Glide HTVS or Glide SP
(Fig 33). Early recognition, in terms of BedROC (α = 8.0, α = 20.0) or RIE, also improved using
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either Glide HTVS or SP (Fig 34) with Amber MD/HSA bridging waters. BedROC and RIE results
using Glide HTVS or SP were comparable for better for the high-resolution δ-OR (PDB ID: 4N6H)
than for the low-resolution δ-OR (PDB ID: 4EJ4). Early enrichment, as measured by enrichment
factors, improved (1%, 2%, 5%, and 10%) with the inclusion of Amber MD/HSA bridging waters
(Fig 35) for both the high- and low-resolution δ-OR but, again, the high-resolution δ-OR
performed somewhat better. In all cases, the most significant results were obtained for
enrichment to the top 1 and 2%. Using Glide HTVS, most known δ-OR agonists with
benzomorphan cores that successfully docked (63/69) did so with reasonable poses (RMSD < 2.00
Å) without bridging waters (Fig 37). In the presence of Amber MD/HSA bridging waters, (56/74)
docked ligands with benzomorphan cores enjoyed reasonable ligand poses and generally
decreased GScores. Some known δ-OR agonists without benzomorphan cores also enjoyed
decreased GScores. Using Glide SP, most known δ-OR agonists with benzomorphan cores that
successfully docked (67/75) did so with reasonable poses (RMSD < 2.00 Å) without bridging
waters (Fig 38). In the presence of Amber MD/HSA bridging waters, (52/74) docked ligands with
benzomorphan cores enjoyed reasonable ligand poses and generally decreased GScores. Some
known δ-OR agonists without benzomorphan cores also enjoyed decreased GScores. The postprocessing script removed ligands below the ΣΔGScores cutoff (kJ/mol) (Fig 36). The remaining
ligands were treated as the top 1% or 2%. Using Glide HTVS against the low- and high-resolution
δ-ORs, the best results were obtained using cutoffs between 0.80 and 1.10 kJ/mol for the top 2%
and using 1.30 and 1.50 kJ/mol for the top 1%. Using Glide SP, the best results were obtained
using cutoffs between 0.50 and 0.70 kJ/mol for the top 2% and using 0.85 and 0.95 kJ/mol for
the top 1%.
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The resulting so-called "equivalent enrichment factors" generally failed to improve the
enrichment factors obtained only from docking, but the equivalent enrichment factor was
significantly better for the high-resolution δ-OR using Glide SP. Using Glide HTVS followed by the
selection script to remove ligands that docked below the ΣΔGScores cutoff (kJ/mol), 27 known δOR agonists remained in the top 1%, and 37 known δ-OR agonists in the top 2% (Fig 37). Of the
δ-OR agonists in the top 1%, 18/27 featured benzomorphan cores and 9/27 did not contain a
benzomorphan core. Of the δ-OR agonists in the top 2%, 26/37 featured benzomorphan cores
and 11/37 did not contain a benzomorphan core. Using Glide SP followed by the selection script
to remove ligands that docked below the ΣΔGScores cutoff (kJ/mol), 60 known δ-OR agonists
remained in the top 1%, and 63 in the top 2% (Fig 38). Of the δ-OR agonists in the top 1%, 31/60
featured benzomorphan cores and 29/60 did not contain a benzomorphan core. Of the δ-OR
agonists in the top 2%, 31/63 featured benzomorphan cores and 32/63 did not contain a
benzomorphan core.

Docking of µ-OR agonists to inactive δ-ORs using Amber MD/HSA bridging waters
We found that the x-ray crystal structure model of the inactive high-resolution δ-OR can
be used with probable locations and orientations of purported bridging waters (obtained using
Amber MD/HSA) to only somewhat improve overall enrichment, early recognition, and early
enrichment of known µ-OR agonists, using Glide HTVS or Glide SP. The post-processing script for
further improvements worked well using Glide SP against the high-resolution δ-OR. Ligandreceptor docking of µ-OR agonists to the low-resolution δ-OR (PDB ID: 4EJ4) and the highresolution δ-OR (PDB ID: 4N6H) using Amber MD/HSA bridging waters produced some
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improvement to overall enrichment when compared to docking without waters using Glide HTVS
and relatively more overall enrichment using Glide SP, as measured by AUC values (Fig 39).
Overall results were somewhat better for the high-resolution δ-OR. Early recognition (BedROC {α
= 8.0, α = 20.0} or RIE) also improved using either Glide HTVS or SP (Fig 40) with Amber MD/HSA
bridging waters as compared to docking without waters. Glide SP performed somewhat better
than Glide HTVS. BedROC and RIE results were better for the high-resolution δ-OR (PDB ID: 4N6H)
than for the low-resolution δ-OR (PDB ID: 4EJ4). Early enrichment, as measured by enrichment
factors, improved (1%, 2%, 5%, and 10%) with the inclusion of Amber MD/HSA bridging waters
(Fig 41) for both the high- and low-resolution δ-OR but the high-resolution δ-OR performed
slightly better. In all cases, the most significant results were obtained for enrichment to the top
1 and 2%. The post-processing script removed ligands below the ΣΔGScores cutoff (Fig 42). The
remaining ligands were treated as the top 1% or 2%. Using Glide HTVS against the low- and highresolution δ-ORs, the best results were obtained using cutoffs between 0.70 and 1.05 kJ/mol for
the top 2% and using 0.95 and 1.05 kJ/mol for the top 1%. Using Glide SP, the best results were
obtained using cutoffs between 0.50 and 0.70 kJ/mol for the top 2% and using 0.95 and 1.05
kJ/mol for the top 1%. The resulting so-called "equivalent enrichment factors" failed to improve
enrichment for Glide HTVS runs, but the "equivalent enrichment factors" were better using Glide
SP for both the low- and high-resolution δ-ORs, though results were superior for Glide SP against
the high-resolution δ-OR. Using Glide HTVS, most known µ-OR agonists with benzomorphan
cores that successfully docked (33/42) did so with reasonable poses (RMSD < 2.00 Å) without
bridging waters (Fig 43). In the presence of Amber MD/HSA bridging waters, (29/44) docked
ligands with benzomorphan cores enjoyed reasonable ligand poses and generally decreased
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GScores. Some known µ-OR agonists without benzomorphan cores also enjoyed decreased
GScores. Using Glide SP, most known µ-OR agonists with benzomorphan cores that successfully
docked (34/46) did so with reasonable poses (RMSD < 2.00 Å) without bridging waters (Fig 44).
In the presence of Amber MD/HSA bridging waters, (29/46) docked ligands with benzomorphan
cores enjoyed reasonable ligand poses and generally decreased GScores. Some known δ-OR
agonists without benzomorphan cores also enjoyed decreased GScores. Using Glide SP followed
by the selection script to remove ligands that docked below the ΣΔGScores cutoff, 30 known µOR agonists remained in the top 1%, and the same 30 agonists in the top 2%. Of the δ-OR agonists
in the top 1% and 2%, 25/30 featured benzomorphan cores and 5/30 did not contain a
benzomorphan core.

Isolated Effects of Bridging Waters
This work isolated the effects of the addition of bridging water molecules by making no
attempt to improve ligand-receptor docking enrichment for each receptor outside of the addition
of a single set of bridging waters (locations and orientations) generated using each technique
(Maestro or Amber MD/HSA). The results, therefore, are relevant specifically to the inclusion of
bridging waters and they may be affected by additional changes to the docking procedure or by
changes in the locations and orientations of bridging waters. Glide HTVS and Glide SP were used
to compare performance while Glide XP was used to break down the contributions to GScores.
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Changing GScores
The inclusion of bridging waters tends to reduce GScores for known actives through
formation of hydrogen bonds and more favorable electrostatic interactions between the known
active ligand and the receptor (Figs 23, 24). The structurally similar decoys tended to suffer
increasing GScores with the inclusion of bridging waters (Figs 19, 31).

Glide HTVS or Glide SP
For the most part, ligand-receptor docking using Glide HTVS or Glide SP produced similar
results. For δ-OR antagonists docked to the high-resolution inactive δ-OR, Glide HTVS and Glide
SP, with either the Maestro or Amber MD/HSA set of bridging waters, generally produced similar
results for early recognition and early enrichment, particularly at 1% and 2% (Figs 17, 18, 25). For
δ-OR antagonists docked to the low-resolution inactive δ-OR with an Amber MD/HSA set of
bridging waters, Glide HTVS and Glide SP performed about the same for early recognition and
early enrichment (Figs 29, 30).
For δ-OR agonists docked to the low-resolution inactive δ-OR with an Amber MD/HSA set
of bridging waters, Glide HTVS performed slightly better than Glide SP for overall enrichment (Fig
33) but for the high-resolution inactive δ-OR, Glide SP performed slightly better than Glide HTVS
for overall enrichment (Fig 33). For δ-OR agonists docked to the low-resolution inactive δ-OR with
an Amber MD/HSA set of bridging waters, Glide HTVS and Glide SP performed about the same
for early recognition (Fig 34). For δ-OR agonists docked to the high-resolution inactive δ-OR with
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an Amber MD/HSA set of bridging waters, Glide SP performed slightly better than Glide HTVS for
early recognition (Fig 34). For δ-OR agonists docked to the low- and high-resolution inactive δORs with an Amber MD/HSA set of bridging waters, Glide HTVS and Glide SP performed about
the same for early enrichment to the top 1% or 2% (Fig 35).
For µ-OR agonists docked to the low- and high-resolution inactive δ-OR with an Amber
MD/HSA set of bridging waters, Glide HTVS and Glide SP performed about the same for overall
enrichment, early recognition, and early enrichment (for the top 1% or 2%) (Fig 39-41).
Glide HTVS sometimes performed better than Glide SP. For µ-OR and κ-OR antagonists
docked to the inactive µ-OR and κ-OR, respectively, with Maestro waters, Glide HTVS performed
better than Glide SP across reported metrics for overall enrichment, early recognition, and early
enrichment (Figs 10-12). These cases were unusual because the inactive µ-OR (PDB ID: 4DKL)
featured only two of the expected bridging waters probably because the resolution of the
receptor wasn’t high enough to resolve the third water, so the third water was added by aligning
the high-resolution δ-OR (PDB ID: 4N6H), then copying the third bridging water to µ-OR and,
finally, minimizing all three waters in the presence of the receptor and ligand. In the case of κ-OR
(PDB ID: 4DJH), a fourth bridging water was located inside the orthosteric binding pocket on the
opposite side from our target bridging waters, and the additional water did interact with the cocrystallized ligand. These unusual factors may have affected the docking results from Glide HTVS
and or Glide SP.
However, Glide SP performed better for overall enrichment for δ-OR antagonists docked
to the low-resolution inactive δ-OR, using Glide HTVS or Glide SP with an Amber MD/HSA set of
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bridging waters (Fig 28). Interestingly, this is the result for the low-resolution δ-OR (PDB ID: 4EJ4)
for which no bridging waters were resolved.

Amber MD/HSA or Maestro Bridging Waters
For δ-OR antagonists docked to the high-resolution inactive δ-OR using Maestro or Amber
MD/HSA waters, Maestro waters performed slightly better (Glide HTVS) or significantly better
(Glide SP) for overall enrichment (Fig 16), though overall enrichment results from docking
without any water molecules reveal that the Amber MD output structure performed less well
than the structure prepared in Maestro without any molecular dynamics simulation, and this may
have affected the results. For δ-OR antagonists docked to the high-resolution inactive δ-OR using
Maestro or Amber MD/HSA waters, using either set of bridging waters (Maestro or Amber
MD/HSA), results were similar for early recognition (Fig 17). As measured by early enrichment,
Maestro waters performed somewhat better than Amber MD/HSA waters (top 1% and 2%) using
Glide HTVS, but Amber MD/HSA waters performed better than Maestro waters (top 1%) using
Glide SP, yet for the top 5% and 10%, the results were otherwise similar (Fig 18).
For δ-OR antagonists docked to the low-resolution inactive δ-OR, it was impossible to use
Maestro waters as the structure was of sufficiently low-resolution that oxygen densities were not
included as purported water molecules in the PDB file, so Amber MD/HSA waters were the only
option (Fig 28).
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The Problem with Active µ-OR
For µ-OR agonists docked to the active µ-OR, results across reported metrics for overall
enrichment, early recognition, and early enrichment were weak and only marginally improved
with the inclusion of bridging waters, which is likely due to issues with the presence of the Nterminus (Figs 13-15).

Post-processing Improvements
Interestingly, the post-processing script can sometimes be used salvage poor docking runs
to produce an acceptable early enrichment to the top 1% or 2% of docked ligands. The postprocessing script performed best using output from Glide SP. The script worked best for some of
the sub-optimal ligand-receptor docking runs such as the failed µ-OR agonists docked to the
active µ-OR in the absence of the N-terminal (Fig 15), the docking of κ-OR antagonists to the
inactive κ-OR (Fig 12), the docking of δ-OR agonists to the high-resolution inactive δ-OR (Fig 36),
and the docking of µ-OR agonists to the high-resolution inactive δ-OR (Fig 42). Glide SP docking
runs tended to retain more actives than Glide HTVS due to the larger number of known actives
fitting the selection criteria of the script (Figs 12, 15, 36, 42). Docking of δ-OR antagonists to the
low-resolution δ-OR with Amber MD/HSA waters, using Glide HTVS or Glide SP, followed by postprocessing produced deleterious results due to loss of known actives (Fig 25).

Early Enrichment of Divergent Ligand Cores
We wanted to assess the effects of the inclusion of Amber MD/HSA bridging waters on
the enrichment of ligands without a benzomorphan core. The co-crystallized ligand, NTI, found
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in the high-resolution δ-OR (PDB ID: 4N6H) contains a benzomorphan core (Fig 21). When docking
to this x-ray crystal structure model, we expected a preference for δ-OR antagonists containing
a benzomorphan core (Fig 20). For the relatively small δ-OR antagonist library docked to the highresolution inactive δ-OR model, using either Glide HTVS or Glide SP, no ligand without a
benzomorphan core (3/15) was enriched above 5% even in the presence of bridging waters (Figs
26, 27). Due to the small sample size, the δ-OR antagonist library is insufficient to eliminate the
possibility that ligands with other cores are likely to be enriched. Docking enrichment of ligands
with divergent cores could be helpful in the search to identify leads for the development of novel
painkillers.
Docking of the δ-OR agonist library to the high-resolution inactive δ-OR model using Glide
HTVS, followed by post-processing, enriched (into the top 2%) 26/74 known δ-OR agonists with
a benzomorphan core and 11/247 known δ-OR agonists without a benzomorphan core. The top
1% contained 18/74 known agonists with a benzomorphan core and 9/247 known agonists
without a benzomorphan core (Fig 37). Using Glide SP, 31/74 known δ-OR agonists with a
benzomorphan core and 32/275 known δ-OR agonists without a benzomorphan core were
enriched into the top 2%, and 31/74 known agonists with a benzomorphan core and 29/275
known agonists without a benzomorphan core were enriched into the top 1% (Fig 38).
Docking of the µ-OR agonist library to the high-resolution inactive δ-OR model using Glide
SP, followed by post-processing, enriched (into the top 2%) 25/46 known µ-OR agonists with a
benzomorphan core and 5/86 known δ-OR agonists without a benzomorphan core. The top 1%
also contained 25/46 known agonists with a benzomorphan core and 5/86 known agonists
without a benzomorphan core (Fig 44).
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The µ-OR and δ-OR share many ligands, so the enrichment of “δ-OR” agonists that also
activate µ-OR is unsurprising. However, the point remains that ligand-receptor docking against
the inactive x-ray crystal structure model of the δ-OR with the inclusion of Amber MD/HSA
bridging waters can be used to improve early enrichment to the top 1% or 2%, in some cases, of
δ-OR and µ-OR antagonists and agonists, even if the conditions are sub-optimal, and some of
these ligands may contain core structures unlike that found in the co-crystallized ligand core, the
benzomorphan core, in this case.
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7 Conclusion
In this work, we demonstrated that water molecules can be useful for lead generation in
drug discovery when docking to opioid receptors or targeting SARS-CoV-2 proteins for scoring of
docking, lead modification, and pharmacophore creation or pharmacophore element selection.
We demonstrated that water molecule positions obtained from high-resolution x-ray crystal
structures or water positions and orientations obtained from processing the output of molecular
dynamics simulations can be useful for lead generation. We found that Hydration Site Analysis
(HSA) applied to MD simulations could be used against low-resolution x-ray crystal structure
models to locate and orient water molecules that were not resolved in the experiment, and that
using these waters improved docking performance. The inclusion of select explicit waters, taken
from x-ray crystal structure models or predicted using MD simulations, during ligand-receptor
docking, improved docked poses for some ligands and, for most known actives, improved overall
docking performance as measured by area under the curve (AUC), enrichment factors (EF),
Boltzmann-enhanced discrimination of receiver operating characteristic (BedROC), and robust
initial enhancement (RIE). Inclusion of explicit bridging waters when docking to opioid receptors
can improve early enrichment of known actives because interactions between the ligand and
bridging waters enhanced the predicted binding affinities of known actives via increased H-bond
and electrostatic interactions between the ligand and receptor, with minimal deleterious effects
observed due to Van der Waals interactions. But decoys, for the most part, did not enjoy
enhanced binding affinities. Rather, even structurally similar decoys tended to suffer diminished
predicted binding affinities with the inclusion of bridging waters. These predictable changes in
ligand-receptor interactions of known active opioids (due to docking in the presence versus the
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absence of mediating waters) could be used to automate the identification of active compounds
that favorably interacted with bridging waters, ligands for whom the interactions with bridging
water molecules are important. We found energetically unfavorable water sites that could be
used against SARS-CoV-2 viral proteins to create water-based pharmacophores and hybrid
pharmacophores, or that could be used to prioritize structure- or ligand-based pharmacophore
elements. Together, these pharmacophore sites could be used to screen virtual compounds
databases. Inside the substrate binding site of the SARS-CoV-2 main protease, using HSA, we
found thermodynamically unfavorable water molecules that could be used to direct the design
of chemical modifications to lead compounds or chemical fragments, and that such modifications
to displace these waters could lead to boosts in binding affinity. Using GIST, we found high-energy
and high-density voxels inside the binding site that could be used as a displaced solvent functional
that could improve pose prediction, for predictions of differences in binding affinities between
congeneric pairs of ligands, for docking enrichment, or to identify new tightly binding compounds.
Taken altogether, we found that water molecules and thermodynamic data obtained using HSA
or GIST can be useful for water-based lead generation against opioid receptors and SARS-CoV-2
proteins.
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8 Future Work
A Teaching and Learning Center grant from the Graduate Center of the City University of
New York, obtained by Brian Olson and Anthony Cruz, enabled the purchase of equipment for
use as a virtual reality station. This workstation was used to pitch the County College of Morris
to create a designated space for a virtual reality lab. The space was assigned, reorganized, and
the college received a Perkins grant to purchase equipment to build out the lab. The lab includes
over a dozen workstations, numerous additional laptops with Oculus Rift headsets, many Oculus
Quest headsets, 3D scanners, various types of stereo and 3D cameras, spatial audio recording
devices, and in-house virtual reality death scenes created as an interdepartmental collaboration
for my forensic science course. One of our VR scenes was featured on PBS/NJTV.
The VR Lab is currently used for education, VR experience development, and SARS-CoV-2
research. Several faculty members (biologist, medicinal chemist, and game developer) have been
recruited to work with me in Nanome (VR software) using Oculus headsets to gamify teaching of
molecular biology and organic chemistry while doing socially relevant research. We use the main
protease of SARS-CoV-2 to study one protein structure in depth and gamers (students) learn
fundamental science during the process. HSA water data from the research in this dissertation is
downloaded from Nanome, the PDB files are modified, and then the files are imported into
Nanome where they can be used for rational lead modification.
We use regional selection and various visualizations of the SARS-CoV-2 main protease to
teach the structures of amino acids, and primary, secondary, tertiary, and quaternary structures
of proteins. We cover common organic atoms, intramolecular bonds, polarity, functional groups,
and drug-like structures. Gamers learn about substrate catalysis and enzyme inhibitors. We cover
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the basic function of the protease while learning the structural regions of the protein with an
emphasis on the main protease active site, and intermolecular bonds between drug molecules
and residues in the binding pocket. Finally, we learn about water displacement and drug binding
in an active site with some analysis of water and energy. Then players attempt to design drugs to
inhibit SARS-CoV-2 main protease.
At this time, we’ve imported Hydration Site Analysis output files into Nanome VR software.
This work has been presented at the National Institute for Staff and Organizational Development
(NISOD) and at Raritan Valley Community College (RVCC) C2 Summit for Pedagogical
Advancements in STEM. We are currently working on tutorials to demonstrate the use of the
water data in Nanome for rational drug design.
We plan to shift our efforts to the use of GIST data in Nanome. In order to do that, we will
need to convert GIST output files in Data Explorer “DX” format into another format that can be
viewed in Nanome. Our team is currently exploring grant writing options for purposes of
education and to fund the adaptation of GIST output files for Nanome so the data can be made
available for educational purposes and research in institutions geared primarily toward teaching.
We aim to create a low-cost opportunity for community college students to engage with their
professors in fundamental science education and socially relevant research using virtual reality
headsets and collaborations with external labs combined with output data from GIST, which is
freely available. We will enable interdisciplinary collaboration to propel learning while doing
authentic research with potential for great social impact.
Ligand structures will be designed in virtual reality based on HSA and GIST output data
combined with ligand cores and fragments obtained by aligning SARS-CoV-2 main protease x-ray
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crystal structure models from the Protein Data Bank. We will build ligands from the ligand cores
and fragments, dock the resulting designed structures, and run MD simulations to validate the
docked ligand structures. Successfully docked ligands that appear to be stable will be ordered, if
the ligands already exist, or synthesized by collaborators, and tested against SARS-CoV-2 main
protease to experimentally determine the binding affinity of the designed ligand.
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